46 results on '"Lemarié CA"'
Search Results
2. Extracellular RNA Induces Neutrophil Recruitment Via Toll-Like Receptor 3 During Venous Thrombosis After Vascular Injury.
- Author
-
Najem MY, Rys RN, Laurance S, Bertin FR, Gourdou-Latyszenok V, Gourhant L, Le Gall L, Le Corre R, Couturaud F, Blostein MD, and Lemarié CA
- Subjects
- Animals, Humans, Signal Transduction, HEK293 Cells, Vascular System Injuries metabolism, Vascular System Injuries genetics, Vascular System Injuries pathology, Neutrophils metabolism, RNA genetics, Male, Mice, Poly I-C pharmacology, Blood Coagulation, Toll-Like Receptor 3 metabolism, Toll-Like Receptor 3 genetics, Venous Thrombosis metabolism, Venous Thrombosis genetics, Venous Thrombosis pathology, Disease Models, Animal, Neutrophil Infiltration, Mice, Knockout, Mice, Inbred C57BL, Human Umbilical Vein Endothelial Cells metabolism
- Abstract
Background: Venous thromboembolism is associated with endothelial cell activation that contributes to the inflammation-dependent activation of the coagulation system. Cellular damage is associated with the release of different species of extracellular RNA (eRNA) involved in inflammation and coagulation. TLR3 (toll-like receptor 3), which recognizes (viral) single-stranded or double-stranded RNAs and self-RNA fragments, might be the receptor of these species of eRNA during venous thromboembolism. Here, we investigate how the TLR3/eRNA axis contributes to venous thromboembolism., Methods and Results: Thrombus formation and size in wild-type and TLR3 deficient (-/-) mice were monitored by ultrasonography after venous thrombosis induction using the ferric chloride and stasis models. Mice were treated with RNase I, with polyinosinic-polycytidylic acid, a TLR3 agonist, or with RNA extracted from murine endothelial cells. Gene expression and signaling pathway activation were analyzed in HEK293T cells overexpressing TLR3 in response to eRNA or in human umbilical vein endothelial cells transfected with a small interference RNA against TLR3. Plasma clot formation on treated human umbilical vein endothelial cells was analyzed. Thrombosis exacerbated eRNA release in vivo and increased eRNA content within the thrombus. RNase I treatment reduced thrombus size compared with vehicle-treated mice ( P <0.05). Polyinosinic-polycytidylic acid and eRNA treatments increased thrombus size in wild-type mice ( P <0.01 and P <0.05), but not in TLR3
-/- mice, by reinforcing neutrophil recruitment ( P <0.05). Mechanistically, TLR3 activation in endothelial cells promotes CXCL5 (C-X-C motif chemokine 5) secretion ( P <0.001) and NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) activation ( P <0.05). Finally, eRNA triggered plasma clot formation in vitro ( P <0.01)., Conclusions: We show that eRNA and TLR3 activation enhance venous thromboembolism through neutrophil recruitment possibly through secretion of CXCL5, a potent neutrophil chemoattractant.- Published
- 2024
- Full Text
- View/download PDF
3. Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: Post-hoc analysis of the PEP trial.
- Author
-
Rambaud G, Mai V, Motreff C, Sanchez O, Roy PM, Auffret Y, Le Mao R, Gagnadoux F, Paleiron N, Schmidt J, Pastre J, Nonent M, Tromeur C, Salaun PY, Mismetti P, Girard P, Lacut K, Lemarié CA, Meyer G, Leroyer C, Le Gal G, Bertoletti L, and Couturaud F
- Subjects
- Humans, Prospective Studies, Algorithms, Fibrin Fibrinogen Degradation Products, Venous Thromboembolism diagnosis, Venous Thromboembolism epidemiology, Pulmonary Embolism complications, Pulmonary Embolism diagnosis, Pulmonary Embolism epidemiology, Pulmonary Disease, Chronic Obstructive complications, Pulmonary Disease, Chronic Obstructive diagnosis
- Abstract
Background: The prevalence of pulmonary embolism (PE) is approximately 11-17 % in patients with an acute exacerbation of chronic obstructive pulmonary disease (AE-COPD). The optimal diagnostic strategy for PE in these patients remains undetermined., Aims: To evaluate the safety and efficacy of standard (revised Geneva and Wells PE scores combined with fixed D-dimer cut-off) and computed tomography pulmonary angiogram (CTPA)-sparing diagnostic strategies (ADJUST-PE, YEARS, PEGeD, 4PEPS) in patients with AE-COPD., Method: Post-hoc analyses of data from the multicenter prospective PEP study were performed. The primary outcome was the diagnostic failure rate of venous thromboembolism (VTE) during the entire study period. Secondary outcomes included diagnostic failure rate of PE and deep venous thrombosis (DVT), respectively, during the entire study period and the number of CTPA needed per diagnostic strategy., Results: 740 patients were included. The revised Geneva and Wells PE scores combined with fixed D-dimer cut-off had a diagnostic failure rate of VTE of 0.7 % (95%CI 0.3 %-1.7 %), but >70.0 % of the patients needed imaging. All CTPA-sparing diagnostic algorithms reduced the need for CTPAs (-10.1 % to -32.4 %, depending on the algorithm), at the cost of an increased VTE diagnosis failure rate of up to 2.1 % (95%CI 1.2 %-3.4 %)., Conclusion: Revised Geneva and Wells PE scores combined with fixed D-dimer cut-off were safe, but a high number of CTPA remained needed. CTPA-sparing algorithms would reduce imaging, at the cost of an increased VTE diagnosis failure rate that exceeds the safety threshold. Further studies are needed to improve diagnostic management in this population., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Couturaud reports having received research grant support from Bristol-Myers Squibb/Pfizer and Bayer and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer, Merck Sharp and Dohme, Merck Sharp and Dohme, Sanofi, Leo Pharma, Janssen and Astra Zeneca and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Leo Pharma, Pfizer. Dr. Bertoletti reports having received research grant support from Bayer and fees for board memberships or symposia from Actelion, Aspen, Bayer, Bristol-Myers Squibb/Pfizer and MSD, and having received travel support from Aspen, Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Leo Pharma, MSD and Actelion. Dr. Pastre declares he has no conflict of interest related to this research. Dr. Roy declares he has no conflict of interest related to this research. Dr. Rambaud declares he has no conflict of interest related to this research. Dr. Mai declares she has no conflict of interest related to this research. Dr. Motreff declares she has no conflict of interest related to this research. Dr. Auffret declares he has no conflict of interest related to this research. Dr. Le Mao declares he has no conflict of interest related to this research. Dr. Gagnadoux declares he has no conflict of interest related to this research. Dr. Paleiron declares he has no conflict of interest related to this research. Dr. Schmidt declares he has no conflict of interest related to this research. Dr. Schmidt declares he has no conflict of interest related to this research. Dr. Sanchez reports having received research grant support from Bayer, Daiichi-Sankyo and Portola Pharmaceuticals, and fees or non-financial support for consultancy activities from Actelion, GlaxoSmithKline, Boehringer Ingelheim and Chiesi. Dr. Bressollette declares he has no conflict of interest related to this research. Dr. Nonent declares he has no conflict of interest related to this research. Dr. Tromeur declares she has no conflict of interest related to this research. Dr. Salaun declares he has no conflict of interest related to this research. Dr. Mismetti reports having received research grants from Bayer, fees for board memberships from Bayer, Bristol-Myers Squibb/Pfizer and Daiichi Sankyo, for lectures from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo and Sanofi, and for development of educational presentations from Bayer and Bristol-Myers Squibb/Pfizer. Dr. Girard reports having received personal fees and non-financial support from Bayer and Leo Pharma. Dr. Lacut reports having received personal fees from Bayer-Health Care, Bristol-Myers Squibb and Boehringer Ingelheim. Dr. Lemarie declares she has no conflict of interest related to this research. Dr. Meyer reports having received research grant support from Bayer, Boehringer Ingelheim, LEO Pharma Research Foundation and Sanofi, having been an uncompensated board member and a consultant for Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Leo Pharma and Pfizer, and having received travel support from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Leo Pharma and Sanofi. Dr. Leroyer reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer and Astra Zeneca and having received travel support from Bayer, Leo Pharma. No other potential conflict of interest relevant to this article was reported., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
4. Frequency and predictors for chronic thromboembolic pulmonary hypertension after a first unprovoked pulmonary embolism: Results from PADIS studies.
- Author
-
Fauché A, Presles E, Sanchez O, Jaïs X, Le Mao R, Robin P, Pernod G, Bertoletti L, Jego P, Parent F, Lemarié CA, Leven F, Le Roux PY, Salaun PY, Nonent M, Girard P, Lacut K, Savale L, Mélac S, Guégan M, Mismetti P, Laporte S, Leroyer C, Montani D, Couturaud F, and Tromeur C
- Subjects
- Humans, Aged, Risk Factors, Chronic Disease, Anticoagulants therapeutic use, Hypertension, Pulmonary diagnosis, Hypertension, Pulmonary epidemiology, Hypertension, Pulmonary complications, Pulmonary Embolism complications, Pulmonary Embolism diagnosis, Pulmonary Embolism epidemiology
- Abstract
Background: Chronic thromboembolic pulmonary hypertension (CTEPH) is a life-threatening complication of a pulmonary embolism (PE) whose incidence and predictors are not precisely determined., Objective: To determine the frequency and predictors for CTEPH after a first unprovoked PE., Patients/methods: In a randomized trial comparing an additional 18-month warfarin versus placebo in patients after a first unprovoked PE initially treated with vitamin K antagonist for 6 months, we applied recommended CTEPH screening strategies through an 8-year follow-up to determine cumulative incidence of CTEPH. CTEPH predictors were estimated using Cox models. Pulmonary vascular obstruction (PVO) and systolic pulmonary arterial pressure (sPAP) at PE diagnosis and 6 months were studied by receiver operating curves analysis. All CTEPH cases and whether they were incident or prevalent were adjudicated., Results: During a median follow-up of 8.7 years, nine CTEPH cases were diagnosed among 371 patients, with a cumulative incidence of 2.8% (95% confidence interval [CI] 0.95-4.64), and of 1.31% (95% CI 0.01-2.60) after exclusion of five cases adjudicated as prevalent. At PE diagnosis, PVO > 45% and sPAP > 56 mmHg were associated with CTEPH with a hazard ratio (HR) of 33.00 (95% CI 1.64-667.00, p = .02) and 12.50 (95% CI 2.10-74.80, p < .01), respectively. Age > 65 years, lupus anticoagulant antibodies and non-O blood groups were also predictive of CTEPH. PVO > 14% and sPAP > 34 mmHg at 6 months were associated with CTEPH (HR 63.90 [95% CI 3.11-1310.00, p < .01]and HR 17.2 [95% CI 2.75-108, p < .01])., Conclusion: After a first unprovoked PE, CTEPH cumulative incidence was 2.8% during an 8-year follow-up. PVO and sPAP at PE diagnosis and at 6 months were the main predictors for CTEPH diagnosis., (© 2022 International Society on Thrombosis and Haemostasis.)
- Published
- 2022
- Full Text
- View/download PDF
5. Endothelial Cell Phenotype, a Major Determinant of Venous Thrombo-Inflammation.
- Author
-
Pilard M, Ollivier EL, Gourdou-Latyszenok V, Couturaud F, and Lemarié CA
- Abstract
Reduced blood flow velocity in the vein triggers inflammation and is associated with the release into the extracellular space of alarmins or damage-associated molecular patterns (DAMPs). These molecules include extracellular nucleic acids, extracellular purinergic nucleotides (ATP, ADP), cytokines and extracellular HMGB1. They are recognized as a danger signal by immune cells, platelets and endothelial cells. Hence, endothelial cells are capable of sensing environmental cues through a wide variety of receptors expressed at the plasma membrane. The endothelium is then responding by expressing pro-coagulant proteins, including tissue factor, and inflammatory molecules such as cytokines and chemokines involved in the recruitment and activation of platelets and leukocytes. This ultimately leads to thrombosis, which is an active pro-inflammatory process, tightly regulated, that needs to be properly resolved to avoid further vascular damages. These mechanisms are often dysregulated, which promote fibrinolysis defects, activation of the immune system and irreversible vascular damages further contributing to thrombotic and inflammatory processes. The concept of thrombo-inflammation is now widely used to describe the complex interactions between the coagulation and inflammation in various cardiovascular diseases. In endothelial cells, activating signals converge to multiple intracellular pathways leading to phenotypical changes turning them into inflammatory-like cells. Accumulating evidence suggest that endothelial to mesenchymal transition (EndMT) may be a major mechanism of endothelial dysfunction induced during inflammation and thrombosis. EndMT is a biological process where endothelial cells lose their endothelial characteristics and acquire mesenchymal markers and functions. Endothelial dysfunction might play a central role in orchestrating and amplifying thrombo-inflammation thought induction of EndMT processes. Mechanisms regulating endothelial dysfunction have been only partially uncovered in the context of thrombotic diseases. In the present review, we focus on the importance of the endothelial phenotype and discuss how endothelial plasticity may regulate the interplay between thrombosis and inflammation. We discuss how the endothelial cells are sensing and responding to environmental cues and contribute to thrombo-inflammation with a particular focus on venous thromboembolism (VTE). A better understanding of the precise mechanisms involved and the specific role of endothelial cells is needed to characterize VTE incidence and address the risk of recurrent VTE and its sequelae., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Pilard, Ollivier, Gourdou-Latyszenok, Couturaud and Lemarié.)
- Published
- 2022
- Full Text
- View/download PDF
6. The Impact of Pulmonary Vascular Obstruction on the Risk of Recurrence of Pulmonary Embolism: A French Prospective Cohort.
- Author
-
Orione C, Tromeur C, Le Mao R, Le Floch PY, Robin P, Hoffmann C, Bressollette L, Nonent M, Le Roux PY, Salaun PY, Guegan M, Poulhazan E, Lacut K, Leroyer C, Lemarié CA, and Couturaud F
- Subjects
- Adult, Aged, Angiography, Cohort Studies, Female, Follow-Up Studies, France, Humans, Male, Middle Aged, Multivariate Analysis, Proportional Hazards Models, Prospective Studies, Pulmonary Embolism complications, Recurrence, Risk Factors, Treatment Outcome, Venous Thromboembolism complications, Anticoagulants pharmacology, Pulmonary Embolism diagnosis, Venous Thromboembolism diagnosis
- Abstract
Background: We aimed to assess whether high pulmonary vascular obstruction index (PVOI) measured at the time of pulmonary embolism (PE) diagnosis is associated with an increased risk of recurrent venous thromboembolism (VTE)., Study Design and Methods: French prospective cohort of patients with a symptomatic episode of PE diagnosed with spiral computerized tomography pulmonary angiography (CTPA) or ventilation-perfusion (V/Q) lung scan and a follow-up of at least 6 months after anticoagulation discontinuation. PVOI was assessed based on the available diagnostic exam (V/Q lung scan or CTPA). All patients had standardized follow-up and independent clinicians adjudicated all deaths and recurrent VTE events. Main outcome was recurrent VTE after stopping anticoagulation., Results: A total of 418 patients with PE were included. During a median follow-up period of 3.6 (1.2-6.0) years, 109 recurrences occurred. In multivariate analysis, PVOI ≥ 40% was an independent risk factor for recurrence (hazard ratio 1.77, 95% confidence interval 1.20-2.62, p < 0.01), whether PE was provoked by a major transient risk factor or not. A threshold at 41% was identified as the best value associated with the risk of recurrence 6 months after stopping anticoagulation (area under curve = 0.64)., Conclusion: PVOI ≥ 40% at PE diagnosis was an independent risk factor for recurrence VTE. Further prospective validation studies are needed., Competing Interests: F.C. reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer and Astra Zeneca and having received travel support from Bayer, Daiichi Sankyo, Leo Pharma, Intermune, and Actelion. C.O. declares he has no conflict of interest related to this research. C.T. declares she has no conflict of interest related to this research. P.R. declares he has no conflict of interest related to this research. R.L.M. declares he has no conflict of interest related to this research. P.-Y.L.R. declares he has no conflict of interest related to this research. P.-Y.S. declares he has no conflict of interest related to this research. C.H. declares he has no conflict of interest related to this research. L.B. declares he has no conflict of interest related to this research. P.-Y.L.F. declares he has no conflict of interest related to this research. M.N. declares he has no conflict of interest related to this research. M.G. declares she has no conflict of interest related to this research. E.P. declares she has no conflict of interest related to this research. C.A.L. declares she has no conflict of interest related to this research. K.L. reports having received personal fees from Bayer-Health Care, Bristol-Myers Squibb, and Boehringer Ingelheim. C.L. reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer and Astra Zeneca and having received travel support from Bayer, Daiichi Sankyo, Leo Pharma, Intermune, and Actelion. No other potential conflict of interest relevant to this article was reported., (Thieme. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
7. Sex-Specific Effects of Prenatal and Early Life Inorganic and Methylated Arsenic Exposure on Atherosclerotic Plaque Development and Composition in Adult A p o E - / - Mice.
- Author
-
Negro Silva LF, Makhani K, Lemaire M, Lemarié CA, Plourde D, Bolt AM, Chiavatti C, Bohle DS, Lehoux S, Goldberg MS, and Mann KK
- Subjects
- Animals, Arsenicals, Female, Male, Methylation, Methyltransferases genetics, Methyltransferases metabolism, Mice, Mice, Knockout, Pregnancy, Sex Factors, Arsenic toxicity, Plaque, Atherosclerotic chemically induced, Prenatal Exposure Delayed Effects
- Abstract
Background: Epidemiologic studies indicate that early life arsenic exposures are linked to an increased risk of cardiovascular diseases. Different oxidation and methylation states of arsenic exist in the environment and are formed in vivo via the action of arsenic ( + 3 oxidation state) methyltransferase (As3MT). Methylated arsenicals are pro-atherogenic postnatally, but pre- and perinatal effects are unclear. This is particularly important because methylated arsenicals are known to cross the placenta., Objectives: We tested the effects of early life exposure to inorganic and methylated arsenicals on atherosclerotic plaque formation and its composition in apolipoprotein E knock-out ( apoE - / - ) mice and evaluated whether apoE - / - mice lacking As3MT expression were susceptible to this effect., Methods: We exposed apoE - / - or apoE - / - / As 3 MT - / - mice to 200 ppb inorganic or methylated arsenic in the drinking water from conception to weaning and assessed atherosclerotic plaques in the offspring at 18 wk of age. Mixed regression models were used to estimate the mean difference in each outcome relative to controls, adjusting for sex and including a random effects term to account for within-litter clustering., Results: Early life exposure to inorganic arsenic, and more profoundly methylated arsenicals, resulted in significantly larger plaques in the aortic arch and sinus in both sexes. Lipid levels in these plaques were higher without a substantial difference in macrophage numbers. Smooth muscle cell content was not altered, but collagen content was lower. Importantly, there were sex-specific differences in these observations, where males had higher lipids and lower collagen in the plaque, but females did not. In mice lacking As3MT, arsenic did not alter the plaque size, although the size was highly variable. In addition, control apoE - / - / As 3 MT - / - mice had significantly larger plaque size compared with control apoE - / - ., Conclusion: This study shows that early life exposure to inorganic and methylated arsenicals is pro-atherogenic with sex-specific differences in plaque composition and a potential role for As3MT in mice. https://doi.org/10.1289/EHP8171.
- Published
- 2021
- Full Text
- View/download PDF
8. Whole exome sequencing, a hypothesis-free approach to investigate recurrent early miscarriage.
- Author
-
Gourhant L, Bocher O, De Saint Martin L, Ludwig TE, Boland A, Deleuze JF, Merviel P, Dupré PF, Lemarié CA, Couturaud F, Le Maréchal C, Génin E, and Pasquier E
- Subjects
- Abortion, Habitual blood, Adult, Case-Control Studies, Female, Humans, Pregnancy, Transcobalamins genetics, Vitamin B 12 Deficiency complications, Young Adult, Abortion, Habitual genetics, Exome Sequencing
- Abstract
Research Question: Are there genetic determinants shared by unrelated women with unexplained recurrent early miscarriage (REM)?, Design: Thirty REM cases and 30 controls were selected with extreme phenotype among women from Eastern Brittany (France), previously enrolled in an incident case-control study on thrombophilic mutations. Cases and controls were selected based on the number of early miscarriages or live births, respectively. Peripheral blood was collected for DNA extraction at initial visit. The burden of low-frequency variants in the coding part of the genes was compared using whole exome sequencing (WES)., Results: Cases had 3 to 17 early miscarriages (20 cases: ≥5 previous losses). Controls had 1 to 4 live births (20 controls: ≥3 previous live births) and no miscarriages. WES data were available for 29 cases and 30 controls. A total of 209,387 variants were found (mean variant per patient: 59,073.05) with no difference between groups (P = 0.68). The top five most significantly associated genes were ABCA4, NFAM1, TCN2, AL078585.1 and EPS15. Previous studies suggest the involvement of vitamin B12 deficiency in REM. TCN2 encodes for vitamin B12 transporter into cells. Therefore, holotranscobalamin (active vitamin B12) was measured for both cases and controls (81.2 ± 32.1 versus 92.9 ± 34.3 pmol/l, respectively, P = 0.186). Five cases but no controls were below 50 pmol/l (P = 0.052)., Conclusions: This study highlights four new genes of interest in REM, some of which belong to known networks of genes involved in embryonic development (clathrin-mediated endocytosis and ciliary pathway). The study also confirms the involvement of TCN2 (vitamin B12 pathway) in the early first trimester of pregnancy., (Copyright © 2021 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
9. 68 Ga-Labelled Carbon Nanoparticles for Ventilation PET/CT Imaging: Physical Properties Study and Comparison with Technegas®.
- Author
-
Blanc-Béguin F, Eliès P, Robin P, Tripier R, Kervarec N, Lemarié CA, Hennebicq S, Tromeur C, Cogulet V, Salaün PY, and Le Roux PY
- Subjects
- Aerosols, Cellulose chemistry, Nanoparticles ultrastructure, Particle Size, Sodium Chloride chemistry, Spectrometry, X-Ray Emission, Carbon chemistry, Gallium Radioisotopes chemistry, Nanoparticles chemistry, Positron Emission Tomography Computed Tomography, Pulmonary Ventilation, Sodium Pertechnetate Tc 99m chemistry, Staining and Labeling
- Abstract
Purpose: The use of
68 Ga-labelled carbon nanoparticles has been proposed for lung ventilation PET/CT imaging. However, no study has assessed the physical properties of68 Ga-labelled carbon nanoparticles. The aim of this study therefore was to evaluate the shape and size of68 Ga-labelled carbon nanoparticles, and to determine the composition of the aerosol, as opposed to99m Tc-labelled carbon nanoparticles aerosol., Procedures:99m Tc- and68 Ga-labelled carbon nanoparticles, stable gallium carbon nanoparticles, 0.9 % NaCl and 0.1 N HCl-based carbon nanoparticles were produced using an unmodified Technegas® generator, following the usual technique used for clinical Technegas® production. The shape and size of particles were studied by transmission electron microscopy (TEM) after decay of the radioactive samples. The composition of the68 Zn- and99 Tc-labelled carbon nanoparticles aerosols was assessed using scanning electron microscopy (SEM) coupled with energy dispersive X-ray (EDX) analysis after decay of the68 Ga- and99m Tc-labelled carbon nanoparticles, respectively., Results: On TEM, all samples showed similar shape with hexagonally structured primary particles, agglomerated in clusters. The mean diameters of primary stable gallium carbon nanoparticles,99 Tc- and68 Zn-labelled carbon nanoparticles were 22.4 ± 10 nm, 20.9 ± 7.2 nm and 19.8 ± 11.7 nm, respectively., Conclusion: Using Technegas® generator in the usual clinical way,99m Tc- and68 Ga-labelled carbon nanoparticles demonstrated similar shape and diameters in the same size range size. These results support the use of68 Ga-labelled carbon nanoparticles for the assessment of regional lung ventilation function with PET imaging.- Published
- 2021
- Full Text
- View/download PDF
10. A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant.
- Author
-
Morange PE, Peiretti F, Gourhant L, Proust C, Soukarieh O, Pulcrano-Nicolas AS, Saripella GV, Stefanucci L, Lacroix R, Ibrahim-Kosta M, Lemarié CA, Frontini M, Alessi MC, Trégouët DA, and Couturaud F
- Subjects
- Adult, Endothelial Cells metabolism, Female, Genetic Predisposition to Disease, HEK293 Cells, Humans, Lipoproteins genetics, Male, Middle Aged, Mutation genetics, Pedigree, Risk Factors, Thrombophilia pathology, Venous Thromboembolism genetics, Venous Thromboembolism pathology, Venous Thrombosis pathology, Exome Sequencing, Microtubule-Associated Proteins genetics, Plasminogen Activator Inhibitor 1 genetics, Protein Serine-Threonine Kinases genetics, Thrombophilia genetics, Venous Thrombosis genetics
- Abstract
Rare variants outside the classical coagulation cascade might cause inherited thrombosis. We aimed to identify the variant(s) causing venous thromboembolism (VTE) in a family with multiple relatives affected with unprovoked VTE and no thrombophilia defects. We identified by whole exome sequencing an extremely rare Arg to Gln variant (Arg89Gln) in the Microtubule Associated Serine/Threonine Kinase 2 (MAST2) gene that segregates with VTE in the family. Free-tissue factor pathway inhibitor (f-TFPI) plasma levels were significantly decreased in affected family members compared to healthy relatives. Conversely, plasminogen activator inhibitor-1 (PAI-1) levels were significantly higher in affected members than in healthy relatives. RNA sequencing analysis of RNA interference experimental data conducted in endothelial cells revealed that, of the 13,387 detected expressed genes, 2,354 have their level of expression modified by MAST2 knockdown, including SERPINE1 coding for PAI-1 and TFPI. In HEK293 cells overexpressing the MAST2 Gln89 variant, TFPI and SERPINE1 promoter activities were respectively lower and higher than in cells overexpressing the MAST2 wild type. This study identifies a novel thrombophilia-causing Arg89Gln variant in the MAST2 gene that is here proposed as a new molecular player in the etiology of VTE by interfering with hemostatic balance of endothelial cells., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
11. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms.
- Author
-
Couturaud F, Bertoletti L, Pastre J, Roy PM, Le Mao R, Gagnadoux F, Paleiron N, Schmidt J, Sanchez O, De Magalhaes E, Kamara M, Hoffmann C, Bressollette L, Nonent M, Tromeur C, Salaun PY, Barillot S, Gatineau F, Mismetti P, Girard P, Lacut K, Lemarié CA, Meyer G, and Leroyer C
- Subjects
- Aged, Cross-Sectional Studies, Female, Follow-Up Studies, Hospitalization, Humans, Male, Middle Aged, Patient Acuity, Prevalence, Pulmonary Embolism epidemiology, Pulmonary Embolism etiology, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology, Venous Thrombosis etiology, Algorithms, Pulmonary Disease, Chronic Obstructive complications, Pulmonary Embolism diagnosis
- Abstract
Importance: The prevalence of pulmonary embolism in patients with chronic obstructive pulmonary disease (COPD) and acutely worsening respiratory symptoms remains uncertain., Objective: To determine the prevalence of pulmonary embolism in patients with COPD admitted to the hospital for acutely worsening respiratory symptoms., Design, Setting, and Participants: Multicenter cross-sectional study with prospective follow-up conducted in 7 French hospitals. A predefined pulmonary embolism diagnostic algorithm based on Geneva score, D-dimer levels, and spiral computed tomographic pulmonary angiography plus leg compression ultrasound was applied within 48 hours of admission; all patients had 3-month follow-up. Patients were recruited from January 2014 to May 2017 and the final date of follow-up was August 22, 2017., Exposures: Acutely worsening respiratory symptoms in patients with COPD., Main Outcomes and Measures: The primary outcome was pulmonary embolism diagnosed within 48 hours of admission. Key secondary outcome was pulmonary embolism during a 3-month follow-up among patients deemed not to have venous thromboembolism at admission and who did not receive anticoagulant treatment. Other outcomes were venous thromboembolism (pulmonary embolism and/or deep vein thrombosis) at admission and during follow-up, and 3-month mortality, whether venous thromboembolism was clinically suspected or not., Results: Among 740 included patients (mean age, 68.2 years [SD, 10.9 years]; 274 women [37.0%]), pulmonary embolism was confirmed within 48 hours of admission in 44 patients (5.9%; 95% CI, 4.5%-7.9%). Among the 670 patients deemed not to have venous thromboembolism at admission and who did not receive anticoagulation, pulmonary embolism occurred in 5 patients (0.7%; 95% CI, 0.3%-1.7%) during follow-up, including 3 deaths related to pulmonary embolism. The overall 3-month mortality rate was 6.8% (50 of 740; 95% CI, 5.2%-8.8%). The proportion of patients who died during follow-up was higher among those with venous thromboembolism at admission than the proportion of those without it at admission (14 [25.9%] of 54 patients vs 36 [5.2%] of 686; risk difference, 20.7%, 95% CI, 10.7%-33.8%; P < .001). The prevalence of venous thromboembolism was 11.7% (95% CI, 8.6%-15.9%) among patients in whom pulmonary embolism was suspected (n = 299) and was 4.3% (95% CI, 2.8%-6.6%) among those in whom pulmonary embolism was not suspected (n = 441)., Conclusions and Relevance: Among patients with chronic obstructive pulmonary disease admitted to the hospital with an acute worsening of respiratory symptoms, pulmonary embolism was detected in 5.9% of patients using a predefined diagnostic algorithm. Further research is needed to understand the possible role of systematic screening for pulmonary embolism in this patient population.
- Published
- 2021
- Full Text
- View/download PDF
12. Predictors of residual pulmonary vascular obstruction after pulmonary embolism: Results from a prospective cohort study.
- Author
-
Picart G, Robin P, Tromeur C, Orione C, Raj L, Ferrière N, Le Mao R, Le Roux PY, Le Floch PY, Lemarié CA, Nonent M, Leroyer C, Guegan M, Lacut K, Salaün PY, and Couturaud F
- Subjects
- Aged, Cohort Studies, Humans, Lung, Prospective Studies, Risk Factors, Pulmonary Embolism complications, Venous Thromboembolism
- Abstract
Background: We aimed to determine the prevalence of residual pulmonary vascular obstruction (RPVO) after symptomatic pulmonary embolism (PE) and to identify risk factors for RPVO., Methods: On the basis of a prospective cohort of patients with a documented symptomatic venous thromboembolism, we included patients who had an acute PE and underwent a ventilation/perfusion lung scan at 3 to 24 months during the follow-up after PE. RPVO score was assessed for each patient. Initial pulmonary vascular obstruction at PE diagnosis was also assessed when available. Univariable and multivariable analyses were performed with preselected data to identify predictors for persistent defect defined as RPVO ≥ 5%., Results: Among the 537 included patients, 278 (51.8%) had RPVO ≥ 5%, and 191 (35.6%) had RPVO ≥ 10%. In primary multivariate analysis on overall population, age ≥ 65 years (odds ratio [OR] 2.25, 95% CI, 1.45-3.52) and chronic respiratory failure (OR 3.19, 95% CI, 1.22-10.04) were independent predictors of RPVO ≥ 5%. In secondary multivariate analysis restricted to 256 patients with available initial pulmonary vascular obstruction score at index PE (IPVO), age ≥ 65 years (OR 2.78, 95% CI, 1.41-5.53), unprovoked PE (OR 2.11, 95% CI, 1.11-4.07) and IPVO ≥ 20% (OR 2.94, 95% CI, 1.68-5.20) were found to be independent risk factors for RVPO ≥5%., Conclusion: In this selected population of patients with an acute PE, age ≥ 65 years, unprovoked PE and IPVO ≥ 20% at PE diagnosis appeared to be risk factors for residual pulmonary vascular obstruction measured at three to 24 months., Competing Interests: Declaration of competing interest All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr. Picart declares he has no conflict of interest related to this research. Dr. Robin declares he has no conflict of interest related to this research. Dr. Tromeur declares she has no conflict of interest related to this research. Dr. Orione declares he has no conflict of interest related to this research. Ms. Raj declares she has no conflict of interest related to this research. Dr. Ferrieres declares he has no conflict of interest related to this research. Dr. Le Mao declares he has no conflict of interest related to this research. Dr. Le Roux declares he has no conflict of interest related to this research. Dr. Le Floch declares he has no conflict of interest related to this research. Ms. Lemarie declares she has no conflict of interest related to this research. Dr. Nonent declares he has no conflict of interest related to this research. Ms. Guegan declares she has no conflict of interest related to this research. Dr. Le Roux declares he has no conflict of interest related to this research. Dr. Leroyer reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer and Astra Zeneca and having received travel support from Bayer, Daiichi Sankyo, Leo Pharma, Intermune and Actelion. Dr. Lacut reports having received personal fees from Bayer-Health Care, Bristol-Myers Squibb and Boehringer Ingelheim. Dr. Salaun declares he has no conflict of interest related to this research. Dr. Couturaud reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer and Astra Zeneca and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Leo Pharma, Intermune and Actelion. No other potential conflict of interest relevant to this article was reported., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
13. Evaluation of Venous Thromboembolism Recurrence Scores in an Unprovoked Pulmonary Embolism Population: A Post-hoc Analysis of the PADIS-PE trial.
- Author
-
Raj L, Presles E, Le Mao R, Robin P, Sanchez O, Pernod G, Bertoletti L, Jego P, Lemarié CA, Leven F, Hoffmann C, Planquette B, Le Roux PY, Slaun PY, Nonent M, Girard P, Lacut K, Mélac S, Guégan M, Mismetti P, Laporte S, Meyer G, Leroyer C, Tromeur C, and Couturaud F
- Subjects
- Adult, Age Factors, Aged, Duration of Therapy, Female, Fibrin Fibrinogen Degradation Products metabolism, Humans, Male, Middle Aged, Proportional Hazards Models, Pulmonary Embolism diagnostic imaging, Randomized Controlled Trials as Topic, Recurrence, Risk Assessment, Sex Factors, Ventilation-Perfusion Scan, Warfarin therapeutic use, Anticoagulants therapeutic use, Pulmonary Embolism drug therapy, Pulmonary Embolism epidemiology, Venous Thromboembolism epidemiology, Venous Thrombosis epidemiology
- Abstract
Background: We aimed to validate the Men Continue and HERDOO2 (HERDOO2), D-dimer, age, sex, hormonal therapy (DASH), and updated Vienna recurrent venous thromboembolism prediction models in a population composed entirely of first unprovoked pulmonary embolism, and to analyze the impact of the addition of the pulmonary vascular obstruction index (PVOI) on score accuracy., Methods: Analyses were based on the double-blind, randomized PADIS-PE trial, which included 371 unprovoked pulmonary embolism patients initially treated for 6 months, successively randomized to receive an additional 18 months of warfarin or placebo, and subsequently followed-up for 2 years., Results: The HERDOO2, DASH, and updated Vienna scores displayed C-statistics of 0.61 (95% CI 0.54-0.68), 0.60 (95% CI 0.53-0.66), and 0.58 (95% CI 0.51-0.66), respectively. Only the HERDOO2 score identified low recurrence risk patients (<3%/year) after anticoagulation was stopped. When added to either of the prediction models, PVOI measured at pulmonary embolism diagnosis, after 6 months of anticoagulation, or both, improved scores' C-statistics between +0.06 and +0.11 points and consistently led to identifying at least 50% of patients who experienced recurrence but in whom the scores would have indicated against extended anticoagulation., Conclusions: In patients with a first unprovoked pulmonary embolism, the HERDOO2 score is able to identify patients with a low recurrence risk after treatment discontinuation. Addition of PVOI improves accuracy of all scores., Clinical Trials Registration: URL: http://www.controlled-trials.com. Unique identifier: NCT00740883., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
14. Cytokine and chemokine regulation of venous thromboembolism.
- Author
-
Najem MY, Couturaud F, and Lemarié CA
- Subjects
- Animals, Chemokines, Cytokines, Humans, Pulmonary Embolism, Venous Thromboembolism, Venous Thrombosis
- Abstract
Morbidity and mortality from venous thromboembolism (VTE), which refers to deep vein thrombosis and pulmonary embolism, have a substantial effect on the global burden of disease. The field of venous thrombosis research has been dramatically changed over the past 10 years with the improvement of animal models that shed some light on the interaction between inflammation and thrombosis. Important recent advances provided evidence of the implication of the innate immune system in venous thrombosis. In this review, we highlighted the cytokines and chemokines that regulate mechanisms of thrombus formation and resolution. Cytokines are pleiotropic, redundant, and multifunctional endogenous mediators orchestrating the inflammatory responses leading to thrombus formation or resolution. The use of experimental models has revealed the pro-thrombotic activity of some cytokines including interferon-γ, interleukin (IL)-6, chemokine ligand 2, IL-17A, IL-9, IL-1β, and transforming growth factor-β. Other cytokines such as IL-10, tumor necrosis factor-α, and IL-8 appear to promote thrombus resolution in late phase of venous thromboembolism. The purpose of this review is to bring together the current knowledge regarding the cytokines and chemokines that have been involved in thrombosis formation and resolution. We postulate that an imbalance between pro-thrombotic and anti-thrombotic cytokines/chemokines may be involved in the pathophysiology of VTE. However, in-depth basic and clinical research in venous thrombosis is still require to fully understand the precise mechanism of action of these cytokines., (© 2020 International Society on Thrombosis and Haemostasis.)
- Published
- 2020
- Full Text
- View/download PDF
15. Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical Practice-The PADIS-PE Trial.
- Author
-
Raj L, Robin P, Le Mao R, Presles E, Tromeur C, Sanchez O, Pernod G, Bertoletti L, Jego P, Leven F, Lemarié CA, Martin A, Planquette B, Le Roux PY, Salaun PY, Nonent M, Girard P, Lacut K, Melac S, Mismetti P, Laporte S, Meyer G, Leroyer C, and Couturaud F
- Subjects
- Double-Blind Method, Factor VIII metabolism, Female, France epidemiology, Humans, Male, Middle Aged, Practice Guidelines as Topic, Predictive Value of Tests, Prognosis, Pulmonary Embolism epidemiology, Risk, Sensitivity and Specificity, Stenosis, Pulmonary Vein epidemiology, Age Factors, Pulmonary Embolism diagnosis, Stenosis, Pulmonary Vein diagnosis
- Abstract
Background: We aimed to identify risk factors for residual pulmonary vascular obstruction after a first unprovoked pulmonary embolism (PE)., Methods: Analyses were based on data from the double-blind randomized "PADIS-PE" trial that included 371 patients with a first unprovoked PE initially treated during 6 uninterrupted months; all patients underwent baseline ventilation-perfusion lung scanning at inclusion (i.e., after 6 months of anticoagulation). Each patient's pulmonary vascular obstruction indexes (PVOIs) at PE diagnosis and at inclusion were centrally assessed., Results: Among the 371 included patients, residual PVOI was available in 356 patients, and 150 (42.1%) patients had PVOI ≥ 5%. At multivariable analysis, age > 65 years (odds ratio [OR], 2.81, 95% confidence interval [CI], 1.58-5.00), PVOI ≥ 25% at PE diagnosis (OR, 3.53, 95% CI, 1.94-6.41), elevated factor VIII (OR, 3.89, 95% CI, 1.41-10.8), and chronic respiratory disease (OR, 2.18, 95% CI, 1.11-4.26) were independent predictors for residual PVOI ≥ 5%. Patients with ≥ 1 of these factors represented 94.5% (123 patients) of all patients with residual PVOI ≥ 5%., Conclusion: Six months after a first unprovoked PE, age > 65 years, PVOI ≥ 25% at PE diagnosis, elevated factor VIII, or chronic respiratory disease were found to be independent predictors for residual pulmonary vascular obstruction., Clinical Trials Registration: URL: http://www.controlled-trials.com. Unique identifier: NCT00740883., Competing Interests: F.C. reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer, Bristol-Myers Squibb/Pfizer, and Astra Zeneca, and having received travel support from Bayer, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, Boehringer Ingelheim, Leo Pharma, Intermune, and Actelion. L.R. declares she has no conflict of interest related to this research. P.R. declares he has no conflict of interest related to this research. R.L.-M. declares he has no conflict of interest related to this research. E.P. declares she has no conflict of interest related to this research. C.T. declares she has no conflict of interest related to this research. O.S. reports having received research grant support from Bayer, Daiichi Sankyo, and Portola Pharmaceuticals, and fees or nonfinancial support for consultancy activities from Actelion, GlaxoSmithKline, Boehringer Ingelheim, and Chiesi. G.P. declares he has no conflict of interest related to this research. L.B. declares he has no conflict of interest related to this research. C.A.L. declares she has no conflict of interest related to this research. P.J. reports having received personal fees or nonfinancial support from Sanofi, GlaxoSmithKline, Bayer, Boehringer Ingelheim, and Leo Pharma. A.M. declares she has no conflict of interest related to this research. F.L. declares he has no conflict of interest related to this research. P.-Y.L.R. declares he has no conflict of interest related to this research. P.-Y.S. declares he has no conflict of interest related to this research. M.N. declares he has no conflict of interest related to this research. B.P. declares he has no conflict of interest related to this research. P.G. reports having received personal fees and nonfinancial support from Bayer and Leo Pharma. K.L. reports having received personal fees from Bayer-Health Care, Bristol-Myers Squibb, and Boehringer Ingelheim. S.M. declares she has no conflict of interest related to this research. P.M. reports having received research grants from Bayer, fees for board memberships from Bayer, Bristol-Myers Squibb/Pfizer, and Daiichi Sankyo, for lectures from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, Daiichi Sankyo, and Sanofi, and for development of educational presentations from Bayer and Bristol-Myers Squibb/Pfizer. S.L. reports having received research grant support from Bayer and Sanofi, and fees for board memberships or consultancy from Bayer, Boehringer Ingelheim, Leo Pharma, and Sanofi. G.M. reports having received research grant support from Bayer, Boehringer Ingelheim, Leo Pharma, and Sanofi, having been an uncompensated board member and a consultant for Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Leo Pharma, and Pfizer, and having received travel support from Bayer, Boehringer Ingelheim, Daiichi Sankyo, Leo Pharma, and Sanofi. C.L. reports having received research grant support from Pfizer and fees for board memberships or symposia from Bayer and Astra Zeneca and having received travel support from Bayer, Daiichi Sankyo, Leo Pharma, Intermune, and Actelion. No other potential conflict of interest relevant to this article was reported., (Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2019
- Full Text
- View/download PDF
16. Defective bone repair in diclofenac treated C57Bl6 mice with and without lipopolysaccharide induced systemic inflammation.
- Author
-
Ramirez-Garcia-Luna JL, Wong TH, Chan D, Al-Saran Y, Awlia A, Abou-Rjeili M, Ouellet S, Akoury E, Lemarié CA, Henderson JE, and Martineau PA
- Subjects
- Animals, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Endothelial Cells drug effects, Humans, Inflammation chemically induced, Inflammation pathology, Lipopolysaccharides toxicity, Macrophages drug effects, Male, Mice, Orthopedic Procedures adverse effects, Osteoblasts drug effects, Osteoclasts drug effects, Pain diagnostic imaging, Pain pathology, Wounds and Injuries complications, Wounds and Injuries diagnostic imaging, Wounds and Injuries pathology, X-Ray Microtomography, Diclofenac pharmacology, Inflammation drug therapy, Pain drug therapy, Wounds and Injuries drug therapy
- Abstract
Bone repair after trauma or surgical intervention involves a tightly regulated cascade of events that starts with hemostasis and an inflammatory response, which are critical for successful healing. Nonsteroidal anti-inflammatory drugs (NSAID) are routinely prescribed for pain relief despite their potential inhibitory effect on bone repair. The goal of this study was to determine the impact of administration of the non-selective NSAID diclofenac in the inflammatory phase of bone repair in mice with or without lipopolysaccharide-induced systemic inflammation. Repair of femoral window defects was characterized using micro computed tomography imaging and histological analyses at 2 weeks postoperative. The data indicate (a) impaired bone regeneration associated with reduced osteoblast, osteoclast, and macrophage activity; (b) changes in the number, activity, and distribution of mast cells in regenerating bone; and (c) impaired angiogenesis due to a direct toxic effect of diclofenac on vascular endothelial cells. The results of this study provide strong evidence to support the conjecture that administration of NSAIDs in the first 2 weeks after orthopaedic surgery disrupts the healing cascade and exacerbates the negative effects of systemic inflammation on the repair process., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
17. Natural killer cells induce neutrophil extracellular trap formation in venous thrombosis.
- Author
-
Bertin FR, Rys RN, Mathieu C, Laurance S, Lemarié CA, and Blostein MD
- Subjects
- Animals, Cells, Cultured, Coculture Techniques, Disease Models, Animal, Extracellular Traps immunology, Interferon-gamma genetics, Interferon-gamma metabolism, Killer Cells, Natural immunology, Male, Mice, Inbred C57BL, Mice, Knockout, Neutrophils immunology, Signal Transduction, T-Box Domain Proteins genetics, T-Box Domain Proteins metabolism, Vena Cava, Inferior immunology, Venous Thrombosis genetics, Venous Thrombosis immunology, Blood Coagulation, Extracellular Traps metabolism, Killer Cells, Natural metabolism, Neutrophils metabolism, Vena Cava, Inferior metabolism, Venous Thrombosis metabolism
- Abstract
Essentials Neutrophil extracellular traps (NETs) are generated during deep vein thrombosis (DVT). The role of interferon γ (IFNγ) and natural killer (NK) cells in NET formation was studied. IFNγ promote venous thrombosis through NET formation. NK cell depletion reduces DVT. SUMMARY: Background Neutrophils contribute to venous thrombosis through the release of neutrophil extracellular traps (NETs), but the mechanism triggering their formation remains unclear. In vitro data show that interferon (IFN)-γ induces the formation of NETs. Objectives To determine whether IFN-γ and the transcription factor T-box expressed on T cells (Tbet) promote venous thrombosis through neutrophil activation. Methods Venous thrombosis was induced by flow restriction in the inferior vena cava in IFN-γ
-/- , Tbet-/- or wild-type (WT) mice. After 48 h, thrombus size was measured by the use of high-frequency ultrasound. NET formation was determined by immunofluorescence. Results and Conclusions Thrombus formation was reduced in Tbet-/- and IFN-γ-/- mice, suggesting that Tbet/IFN-γ-expressing cells are required for venous thrombosis. The number of NETs formed during thrombosis was significantly lower in Tbet-/- and IFN-γ-/- mice. NET formation was also decreased in WT mice treated with an IFN-γ-blocking antibody. Injection of recombinant IFN-γ into IFN-γ-/- mice rescued the phenotype. Natural killer (NK) cells were specifically depleted prior to venous thrombosis induction. NK cell depletion results in decreased NET formation and smaller thrombi, suggesting that NK cells are required for thrombus development. In depleted mice, adoptive transfer of WT NK cells induced a similar thrombosis burden as in WT mice. In contrast, adoptive transfer of IFN-γ-/- NK cells resulted in thrombi similar in size to those in depleted mice. In vitro, we showed that WT neutrophils released fewer NETs when they were cocultured with IFN-γ-/- NK cells. This study demonstrates that NK cell-dependent IFN-γ production is crucial for thrombus development by promoting the formation of NETs by neutrophils., (© 2018 International Society on Thrombosis and Haemostasis.)- Published
- 2019
- Full Text
- View/download PDF
18. Using the Apolipoprotein E Knock-Out Mouse Model to Define Atherosclerotic Plaque Changes Induced by Low Dose Arsenic.
- Author
-
Makhani K, Chiavatti C, Plourde D, Negro Silva LF, Lemaire M, Lemarié CA, Lehoux S, and Mann KK
- Subjects
- Animals, Aorta drug effects, Aorta metabolism, Aorta pathology, Atherosclerosis metabolism, Atherosclerosis pathology, Disease Models, Animal, Dose-Response Relationship, Drug, Mice, Mice, Knockout, Plaque, Atherosclerotic metabolism, Plaque, Atherosclerotic pathology, Apolipoproteins E genetics, Arsenites toxicity, Atherosclerosis chemically induced, Environmental Pollutants toxicity, Plaque, Atherosclerotic chemically induced
- Abstract
Arsenic exposure increases the risk of atherosclerosis, the gradual occlusion of the large arteries with fibro-fatty plaque. While epidemiologic data provide convincing evidence this is true at higher exposures, it is unclear whether this may occur at low arsenic exposures, near the maximum contaminant level of 10 ppb. We have previously shown that 200 ppb arsenite in the drinking water increased the atherosclerosis in apolipoprotein E knock-out (apoE-/-) mice after 13 weeks, but the effects of lower concentrations were unknown. Therefore, here, we analyzed the effects of oral exposure to arsenite from 10 to 200 ppb after 13 weeks. Importantly, we found that even at the lowest concentration of arsenite, there was a significant increase in atherosclerotic plaque size. In our previous studies, we found that arsenite exposure resulted in decreased smooth muscle cells (SMCs) and collagen within the plaque. This change is indicative of a less stable phenotype that could increase the risk of rupture and subsequently, myocardial infarct or stroke in humans. In addition, we observed that lipid increased within the plaque without concomitant increase in macrophage content, suggesting that the macrophages were retaining more lipid intracellularly. We also assessed these plaque components in apoE-/- mice exposed to 10-200 ppb arsenite. Interestingly, we observed that macrophage lipid accumulation occurred at lower concentrations than the decreased SMC/collagen content. Together these data suggest that in the apoE-/- model, low arsenite concentrations are pro-atherogenic and that macrophage lipid homeostasis is more sensitive to arsenite-induced perturbation than the SMCs.
- Published
- 2018
- Full Text
- View/download PDF
19. Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography.
- Author
-
Rys RN, Blostein MD, and Lemarié CA
- Subjects
- Animals, Disease Models, Animal, Male, Mice, Venous Thrombosis diagnostic imaging, Venous Thrombosis pathology, Ultrasonography methods, Venous Thrombosis etiology
- Abstract
Venous thrombosis is a common condition affecting 1 - 2% of the population, with an annual incidence of 1 in 500. Venous thrombosis can lead to death through pulmonary embolism or results in the post-thrombotic syndrome, characterized by chronic leg pain, swelling, and ulceration, or in chronic pulmonary hypertension resulting in significant chronic respiratory compromise. This is the most common cardiovascular disease after myocardial infarction and ischemic stroke and is a clinical challenge for all medical disciplines, as it can complicate the course of other disorders such as cancer, systemic disease, surgery, and major trauma. Experimental models are necessary to study these mechanisms. The stasis model induces consistent thrombus size and a quantifiable amount of thrombus. However, it is necessary to systematically ligate side branches of the inferior vena cava to avoid variability in thrombus sizes and any erroneous data interpretation. We have developed a non-invasive technique to measure thrombus size using ultrasonography. Using this technique, we can assess thrombus development and resolution over time in the same animal. This approach limits the number of mice required for quantification of venous thrombosis consistent with the principle of replacement, reduction, and refinement of animals in research. We have demonstrated that thrombus weight and histological analysis of thrombus size correlate with measurement obtained with ultrasonography. Therefore, the current study describes how to induce deep vein thrombosis in mice using the inferior vena cava stasis model and how to monitor it using high frequency ultrasound.
- Published
- 2018
- Full Text
- View/download PDF
20. Effects of Inorganic Arsenic, Methylated Arsenicals, and Arsenobetaine on Atherosclerosis in the Mouse Model and the Role of As3mt-Mediated Methylation.
- Author
-
Negro Silva LF, Lemaire M, Lemarié CA, Plourde D, Bolt AM, Chiavatti C, Bohle DS, Slavkovich V, Graziano JH, Lehoux S, and Mann KK
- Subjects
- Animals, Humans, Male, Methylation, Methyltransferases metabolism, Mice, Mice, Knockout, Arsenic toxicity, Arsenicals metabolism, Atherosclerosis chemically induced, Atherosclerosis genetics, Gene Expression, Methyltransferases genetics, Water Pollutants, Chemical toxicity
- Abstract
Background: Arsenic is metabolized through a series of oxidative methylation reactions by arsenic (3) methyltransferase (As3MT) to yield methylated intermediates. Although arsenic exposure is known to increase the risk of atherosclerosis, the contribution of arsenic methylation and As3MT remains undefined., Objectives: Our objective was to define whether methylated arsenic intermediates were proatherogenic and whether arsenic biotransformation by As3MT was required for arsenic-enhanced atherosclerosis., Methods: We utilized the apoE
−/− mouse model to compare atherosclerotic plaque size and composition after inorganic arsenic, methylated arsenical, or arsenobetaine exposure in drinking water. We also generated apoE−/− /As3mt−/− double knockout mice to test whether As3MT-mediated biotransformation was required for the proatherogenic effects of inorganic arsenite. Furthermore, As3MT expression and function were assessed in in vitro cultures of plaque-resident cells. Finally, bone marrow transplantation studies were performed to define the contribution of As3MT-mediated methylation in different cell types to the development of atherosclerosis after inorganic arsenic exposure., Results: We found that methylated arsenicals, but not arsenobetaine, are proatherogenic and that As3MT is required for arsenic to induce reactive oxygen species and promote atherosclerosis. Importantly, As3MT was expressed and functional in multiple plaque-resident cell types, and transplant studies indicated that As3MT is required in extrahepatic tissues to promote atherosclerosis., Conclusion: Taken together, our findings indicate that As3MT acts to promote cardiovascular toxicity of arsenic and suggest that human AS3MT SNPs that correlate with enzyme function could predict those most at risk to develop atherosclerosis among the millions that are exposed to arsenic. https://doi.org/10.1289/EHP806.- Published
- 2017
- Full Text
- View/download PDF
21. Gas6 Promotes Inflammatory (CCR2 hi CX3CR1 lo ) Monocyte Recruitment in Venous Thrombosis.
- Author
-
Laurance S, Bertin FR, Ebrahimian T, Kassim Y, Rys RN, Lehoux S, Lemarié CA, and Blostein MD
- Subjects
- Animals, CX3C Chemokine Receptor 1, Cells, Cultured, Chemokine CCL2 genetics, Chemokine CCL2 metabolism, Clodronic Acid pharmacology, Disease Models, Animal, Endothelial Cells metabolism, Genetic Predisposition to Disease, Inflammation genetics, Inflammation pathology, Inflammation prevention & control, Intercellular Signaling Peptides and Proteins deficiency, Intercellular Signaling Peptides and Proteins genetics, JNK Mitogen-Activated Protein Kinases metabolism, Male, Mice, Inbred C57BL, Mice, Knockout, Monocytes drug effects, Paracrine Communication, Phenotype, Receptors, CCR2 genetics, Signal Transduction, Vena Cava, Inferior drug effects, Vena Cava, Inferior pathology, Venous Thrombosis genetics, Venous Thrombosis pathology, Venous Thrombosis prevention & control, Chemotaxis, Leukocyte drug effects, Inflammation metabolism, Intercellular Signaling Peptides and Proteins metabolism, Monocytes metabolism, Receptors, CCR2 metabolism, Receptors, Chemokine metabolism, Vena Cava, Inferior metabolism, Venous Thrombosis metabolism
- Abstract
Objective: Coagulation and inflammation are inter-related. Gas6 (growth arrest-specific 6) promotes venous thrombosis and participates to inflammation through endothelial-innate immune cell interactions. Innate immune cells can provide the initiating stimulus for venous thrombus development. We hypothesize that Gas6 promotes monocyte recruitment during venous thrombosis., Approach and Results: Deep venous thrombosis was induced in wild-type and Gas6-deficient (-/-) mice using 5% FeCl
3 and flow reduction in the inferior vena cava. Total monocyte depletion was achieved by injection of clodronate before deep venous thrombosis. Inflammatory monocytes were depleted using an anti-C-C chemokine receptor type 2 (CCR2) antibody. Similarly, injection of an anti-chemokine ligand 2 (CCL2) antibody induced CCL2 depletion. Flow cytometry and immunofluorescence were used to characterize the monocytes recruited to the thrombus. In vivo, absence of Gas6 was associated with a reduction of monocyte recruitment in both deep venous thrombosis models. Global monocyte depletion by clodronate leads to smaller thrombi in wild-type mice. Compared with wild type, the thrombi from Gas6-/- mice contain less inflammatory (CCR2hi CX3 CR1lo ) monocytes, consistent with a Gas6-dependent recruitment of this monocyte subset. Correspondingly, selective depletion of CCR2hi CX3 CR1lo monocytes reduced the formation of venous thrombi in wild-type mice demonstrating a predominant role of the inflammatory monocytes in thrombosis. In vitro, the expression of both CCR2 and CCL2 were Gas6 dependent in monocytes and endothelial cells, respectively, impacting monocyte migration. Moreover, Gas6-dependent CCL2 expression and monocyte migration were mediated via JNK (c-Jun N-terminal kinase)., Conclusions: This study demonstrates that Gas6 specifically promotes the recruitment of inflammatory CCR2hi CX3 CR1lo monocytes through the regulation of both CCR2 and CCL2 during deep venous thrombosis., (© 2017 American Heart Association, Inc.)- Published
- 2017
- Full Text
- View/download PDF
22. Prostaglandin E synthase is upregulated by Gas6 during cancer-induced venous thrombosis.
- Author
-
Aghourian MN, Lemarié CA, Bertin FR, and Blostein MD
- Subjects
- Animals, Cells, Cultured, Dinoprostone adverse effects, Dinoprostone metabolism, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Intercellular Signaling Peptides and Proteins genetics, Intramolecular Oxidoreductases metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Neoplasms genetics, Neoplasms pathology, Prostaglandin-E Synthases, Up-Regulation, Venous Thrombosis genetics, Venous Thrombosis pathology, Intercellular Signaling Peptides and Proteins physiology, Intramolecular Oxidoreductases genetics, Neoplasms complications, Venous Thrombosis etiology
- Abstract
Venous thromboembolism is a common complication of cancer. Based on recent evidence that (1) growth arrest-specific 6 (Gas6) regulates the expression of tissue factor during venous thrombosis, and (2) cancer promotes a procoagulant milieu, we hypothesize that Gas6 may be involved in cancer-induced coagulopathy. Venous thrombi were induced in both wild-type (WT) and Gas6-deficient ((-/-)) mice with cancer. WT mice with cancer developed larger thrombi than their healthy counterparts; these larger thrombi induced by cancer were not seen in Gas6(-/-) mice. Whole genome microarray analysis of differential gene expression in WT and Gas6(-/-) endothelial cells exposed to M27 murine lung carcinoma cells reveal that Gas6 increases prostaglandin E synthase (Ptges) expression in endothelial cells. This was confirmed using real-time polymerase chain reaction and immunofluorescence staining. Culture of WT endothelial cells with M27 increases the secretion of prostaglandin E2 (PGE2), the enzymatic product of Ptges, in WT but not in Gas6(-/-) endothelial cells. In WT endothelial cells, Ptges expression was regulated through extracellular signal-regulated kinase 1/2 phosphorylation (ERK1/2). In vitro, PGE2 activates platelets after binding to its receptor, EP3. In vivo, EP3 receptor antagonism reversed the effect of cancer-induced thrombosis in WT mice. These results show that Gas6, through upregulation of PGE2, contributes to cancer-induced venous thrombosis., (© 2016 by The American Society of Hematology.)
- Published
- 2016
- Full Text
- View/download PDF
23. Growth arrest-specific 6 regulates thrombin-induced expression of vascular cell adhesion molecule-1 through forkhead box O1 in endothelial cells.
- Author
-
Bertin FR, Lemarié CA, Robins RS, and Blostein MD
- Subjects
- Animals, Bone Marrow Cells metabolism, Cell Adhesion, Cells, Cultured, Endothelial Cells metabolism, Forkhead Box Protein O1, Forkhead Transcription Factors genetics, Gene Expression Regulation, Genotype, Intercellular Signaling Peptides and Proteins deficiency, Intercellular Signaling Peptides and Proteins genetics, Male, Mice, Inbred C57BL, Mice, Knockout, Mutation, Phenotype, Phosphorylation, Protein Kinase Inhibitors pharmacology, Proto-Oncogene Proteins c-akt antagonists & inhibitors, Proto-Oncogene Proteins c-akt metabolism, RNA Interference, Signal Transduction, Time Factors, Transfection, Vascular Cell Adhesion Molecule-1 genetics, Venous Thromboembolism genetics, Venous Thromboembolism metabolism, Endothelial Cells drug effects, Forkhead Transcription Factors metabolism, Intercellular Signaling Peptides and Proteins metabolism, Thrombin pharmacology, Vascular Cell Adhesion Molecule-1 metabolism
- Abstract
Background: Growth arrest-specific 6 (Gas6)-deficient mice are protected against venous thromboembolism (VTE), suggesting a role for Gas6 in this disorder. We previously demonstrated that Gas6 induces forkhead box O1 (FoxO-1) phosphorylation through the phosphoinositide 3-kinase-Akt pathway. FoxO-1 regulates the expression of vascular cell adhesion molecule-1 (VCAM-1), a molecule that has been implicated in VTE., Objectives: To assess the role of FoxO-1 in Gas6-dependent VCAM-1 expression., Methods: Thrombin was used to stimulate endothelial cells (ECs). Wild-type (WT) and Gas6(-/-) ECs were transfected with small interfering RNA targeting Axl or FoxO-1, a luciferase-coupled plasmid containing the FoxO-1 consensus sequence, and a phosphorylation-resistant FoxO-1 mutant, or treated with an Akt inhibitor. VCAM-1 mRNA expression was measured by real time-qPCR. VCAM-1 protein expression and FoxO-1 and Akt phosphorylation were assessed by western blot analysis. FoxO-1 localization was assessed by immunofluorescence. Adhesion of bone marrow mononuclear cells (BM-MCs) on ECs was assessed by fluorescence., Results and Conclusions: Thrombin induces both VCAM-1 expression and FoxO-1 phosphorylation and nuclear exclusion in WT ECs only. Silencing of FoxO-1 enhances VCAM-1 expression in both WT and Gas6(-/-) ECs. Inhibition of Akt or FoxO-1 phosphorylation prevents VCAM-1 expression in WT ECs. These data show that Gas6 induces FoxO-1 phosphorylation, leading to derepression of VCAM-1 expression. BM-MC-EC adhesion is increased by thrombin in WT ECs. BM-MC-EC adhesion is further increased when FoxO-1 is silenced, but decreased when FoxO-1 phosphorylation is inhibited. These results demonstrate that the Gas6-FoxO-1 signaling axis plays an important role in VCAM-1 expression in the context of VTE by promoting BM-MC-EC adhesion., (© 2015 International Society on Thrombosis and Haemostasis.)
- Published
- 2015
- Full Text
- View/download PDF
24. Arsenic Exposure Increases Monocyte Adhesion to the Vascular Endothelium, a Pro-Atherogenic Mechanism.
- Author
-
Lemaire M, Negro Silva LF, Lemarié CA, Bolt AM, Flores Molina M, Krohn RM, Smits JE, Lehoux S, and Mann KK
- Subjects
- Animals, Antioxidants pharmacology, Atherosclerosis metabolism, Cell Adhesion, Cell Line, Cells, Cultured, Endothelium, Vascular drug effects, Endothelium, Vascular metabolism, Humans, Male, Mice, Mice, Inbred C57BL, Monocytes metabolism, Organ Culture Techniques, Platelet Activation drug effects, Reactive Oxygen Species metabolism, Vascular Cell Adhesion Molecule-1 metabolism, Arsenic adverse effects, Atherosclerosis chemically induced, Atherosclerosis pathology, Endothelium, Vascular pathology, Environmental Pollutants adverse effects, Monocytes drug effects, Monocytes pathology
- Abstract
Epidemiological studies have shown that arsenic exposure increases atherosclerosis, but the mechanisms underlying this relationship are unknown. Monocytes, macrophages and platelets play an important role in the initiation of atherosclerosis. Circulating monocytes and macrophages bind to the activated vascular endothelium and migrate into the sub-endothelium, where they become lipid-laden foam cells. This process can be facilitated by platelets, which favour monocyte recruitment to the lesion. Thus, we assessed the effects of low-to-moderate arsenic exposure on monocyte adhesion to endothelial cells, platelet activation and platelet-monocyte interactions. We observed that arsenic induces human monocyte adhesion to endothelial cells in vitro. These findings were confirmed ex vivo using a murine organ culture system at concentrations as low as 10 ppb. We found that both cell types need to be exposed to arsenic to maximize monocyte adhesion to the endothelium. This adhesion process is specific to monocyte/endothelium interactions. Hence, no effect of arsenic on platelet activation or platelet/leukocyte interaction was observed. We found that arsenic increases adhesion of mononuclear cells via increased CD29 binding to VCAM-1, an adhesion molecule found on activated endothelial cells. Similar results were observed in vivo, where arsenic-exposed mice exhibit increased VCAM-1 expression on endothelial cells and increased CD29 on circulating monocytes. Interestingly, expression of adhesion molecules and increased binding can be inhibited by antioxidants in vitro and in vivo. Together, these data suggest that arsenic might enhance atherosclerosis by increasing monocyte adhesion to endothelial cells, a process that is inhibited by antioxidants.
- Published
- 2015
- Full Text
- View/download PDF
25. Absence of Four-and-a-Half LIM Domain Protein 2 Decreases Atherosclerosis in ApoE-/- Mice.
- Author
-
Ebrahimian T, Simon D, Lemarié CA, Simeone S, Heidari M, Mann KK, Wassmann S, and Lehoux S
- Subjects
- Animals, Atherosclerosis physiopathology, Cell Adhesion Molecules metabolism, Cells, Cultured, Chemokines metabolism, Disease Models, Animal, Endothelial Cells metabolism, Macrophages metabolism, Mice, Mice, Knockout, Myeloid Cells metabolism, Random Allocation, Apolipoproteins E deficiency, Atherosclerosis pathology, Intercellular Adhesion Molecule-1 metabolism, LIM Domain Proteins deficiency
- Abstract
Objective: Four-and-a-half LIM domain protein-2 (FHL2) is expressed in endothelial cells, vascular smooth muscle cells, and leukocytes. It regulates cell survival, migration, and inflammatory response, but its role in atherogenesis is unknown., Approach and Results: To investigate the role of FHL2 in atherosclerosis, FHL2-deficient mice were crossed with ApoE-deficient mice, to generate ApoE/FHL2-/- mice. After high-fat diet, ApoE/FHL2-/- mice had significantly smaller atherosclerotic plaques than ApoE-/- mice in the aortic sinus, the brachiocephalic artery, and the aorta. This was associated with enhanced collagen and smooth muscle cell contents and a 2-fold reduction in macrophage content within the plaques of ApoE/FHL-2-/- versus ApoE-/- mice. This could be explained, in part, by the reduction in aortic ICAM-1 (intracellular adhesion molecule) mRNA and VCAM-1 (vascular cell adhesion molecule) protein expression in the plaque. Aortic gene expression of the chemokines CX3CL1 and CCL5 was increased in ApoE/FHL2-/- versus ApoE-/- mice. Peritoneal thioglycollate injection elicited equivalent numbers of monocytes and macrophages in both groups, but a significantly lower number of proinflammatory Ly6C high monocytes were recruited in ApoE/FHL2-/- versus ApoE-/- mice. Furthermore, mRNA levels of CX3CR1 were 2-fold higher in monocytes from ApoE/FHL2-/- versus ApoE-/- mice. Finally, we investigated the potential importance of myeloid cell FHL2 deficiency in atherosclerosis. After being irradiated, ApoE-/- or ApoE/FHL2-/- mice were transplanted with ApoE-/- or ApoE/FHL2-/- bone marrow. After high-fat diet, both chimeric groups developed smaller plaques than ApoE-/- transplanted with ApoE-/- bone marrow., Conclusions: These results suggest that FHL2 in both myeloid and vascular cells may play an important role in atherosclerosis by promoting proinflammatory chemokine production, adhesion molecule expression, and proinflammatory monocyte recruitment., (© 2015 American Heart Association, Inc.)
- Published
- 2015
- Full Text
- View/download PDF
26. Genetic deletion of LXRα prevents arsenic-enhanced atherosclerosis, but not arsenic-altered plaque composition.
- Author
-
Lemaire M, Lemarié CA, Flores Molina M, Guilbert C, Lehoux S, and Mann KK
- Subjects
- Animals, Aorta drug effects, Aorta metabolism, Aorta pathology, Apolipoproteins E genetics, Apoptosis genetics, Atherosclerosis chemically induced, Atherosclerosis pathology, Atherosclerosis prevention & control, Cell Proliferation genetics, Disease Models, Animal, Lipid Metabolism genetics, Lipids blood, Liver X Receptors, Macrophages drug effects, Macrophages metabolism, Macrophages pathology, Male, Mice, Knockout, Plaque, Atherosclerotic chemically induced, Plaque, Atherosclerotic pathology, Plaque, Atherosclerotic prevention & control, Arsenites toxicity, Atherosclerosis genetics, Environmental Pollutants toxicity, Gene Deletion, Orphan Nuclear Receptors genetics, Plaque, Atherosclerotic genetics, Sodium Compounds toxicity
- Abstract
Arsenic exposure has been linked to an increased incidence of atherosclerosis. Previously, we have shown in vitro and in vivo that arsenic inhibits transcriptional activation of the liver X receptors (LXRs), key regulators of lipid homeostasis. Therefore, we evaluated the role of LXRα in arsenic-induced atherosclerosis using the apoE(-/-) mouse model. Indeed, deletion of LXRα protected apoE(-/-) mice against the proatherogenic effects of arsenic. We have previously shown that arsenic changes the plaque composition in apoE(-/-) mice. Arsenic decreased collagen content in the apoE(-/-) model, and we have observed the same diminution in LXRα(-/-)apoE(-/-) mice. However, the collagen-producing smooth muscle cells (SMCs) were decreased in apoE(-/-), but increased in LXRα(-/-)apoE(-/-). Although transcriptional activation of collagen remained the same in SMC from both genotypes, arsenic-exposed LXRα(-/-)apoE(-/-) plaques had increased matrix metalloproteinase activity compared with both control LXRα(-/-)apoE(-/-) and apoE(-/-), which could be responsible for both the decrease in plaque collagen and the SMC invasion. In addition, arsenic increased plaque lipid accumulation in both genotypes. However, macrophages, the cells known to retain lipid within the plaque, were unchanged in arsenic-exposed apoE(-/-) mice, but decreased in LXRα(-/-)apoE(-/-). We confirmed in vitro that these cells retained more lipid following arsenic exposure and are more sensitive to apoptosis than apoE(-/-). Mice lacking LXRα are resistant to arsenic-enhanced atherosclerosis, but arsenic-exposed LXRα(-/-)apoE(-/-) mice still present a different plaque composition pattern than the arsenic-exposed apoE(-/-) mice., (© The Author 2014. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2014
- Full Text
- View/download PDF
27. Inhibition of four-and-a-half LIM domain protein-2 increases survival, migratory capacity, and paracrine function of human early outgrowth cells through activation of the sphingosine kinase-1 pathway: implications for endothelial regeneration.
- Author
-
Ebrahimian T, Arfa O, Simeone S, Lemarié CA, Lehoux S, and Wassmann S
- Subjects
- Adult, Animals, Apoptosis, Apoptosis Regulatory Proteins metabolism, Carotid Arteries cytology, Cell Survival, Cells, Cultured, Cortactin genetics, Cortactin metabolism, Culture Media, Conditioned pharmacology, Endothelial Cells drug effects, Endothelial Cells physiology, Endothelium, Vascular cytology, Endothelium, Vascular injuries, Endothelium, Vascular metabolism, Enzyme Inhibitors pharmacology, Female, Humans, Integrins genetics, Integrins metabolism, LIM-Homeodomain Proteins antagonists & inhibitors, LIM-Homeodomain Proteins genetics, Leukocytes, Mononuclear metabolism, Leukocytes, Mononuclear physiology, Male, Mice, Mice, Inbred C57BL, Muscle Proteins antagonists & inhibitors, Muscle Proteins genetics, Phosphotransferases (Alcohol Group Acceptor) antagonists & inhibitors, Receptors, Lysosphingolipid antagonists & inhibitors, Receptors, Lysosphingolipid metabolism, Spleen cytology, Transcription Factors antagonists & inhibitors, Transcription Factors genetics, Cell Movement, Endothelial Cells metabolism, LIM-Homeodomain Proteins metabolism, Muscle Proteins metabolism, Paracrine Communication, Phosphotransferases (Alcohol Group Acceptor) metabolism, Transcription Factors metabolism, Wound Healing
- Abstract
Rationale: Inhibition of four-and-a-half LIM domain protein-2 (FHL2) attenuates atherosclerotic lesion formation and increases endothelial cell migration. Early outgrowth cells (EOCs) contribute substantially to endothelial repair., Objective: We investigated the role of FHL2 in the regulation of EOCs., Methods and Results: Human EOCs were cultured from peripheral blood. FHL2 knockdown in EOCs by siRNA resulted in increased EOC numbers and reduced apoptosis, as indicated by decreased cleaved caspase-III and reduced Bax/Bcl-2 expression ratio. This was mediated through increased phosphorylation and membrane translocation of sphingosine kinase-1, increased sphingosine-1-phosphate levels, and Akt phosphorylation. FHL2 knockdown increased stromal cell-derived factor-1-induced EOC migration through upregulation of αv/β3, αv/β5, and β2 integrins, associated with increased cortactin expression. Reduced apoptosis, increased EOC migration, and cortactin upregulation by FHL2 siRNA were prevented by CAY10621, the sphingosine kinase-1 inhibitor, and the sphingosine-1-phosphate receptor-1/-3 antagonist VPC23019. These findings were confirmed using spleen-derived EOCs from FHL2(-/-) mice. Apoptosis was decreased and migration increased in endothelial cells exposed to the conditioned medium of FHL2(-/-) versus wild-type (WT) EOCs. These paracrine effects were abolished by VPC23019. Importantly, reendothelialization after focal carotid endothelial injury in WT mice was significantly increased after intravenous injection of FHL2(-/-) versus WT EOCs., Conclusions: Our findings suggest that FHL2 negatively regulates EOC survival, migration, and paracrine function. FHL2 inhibition in EOCs reduces apoptosis and enhances survival and migratory capacity of both EOCs and surrounding endothelial cells by activation of the sphingosine kinase-1/sphingosine-1-phosphate pathway, resulting in improvement of endothelial regeneration.
- Published
- 2014
- Full Text
- View/download PDF
28. Gas6-induced tissue factor expression in endothelial cells is mediated through caveolin-1-enriched microdomains.
- Author
-
Laurance S, Aghourian MN, Jiva Lila Z, Lemarié CA, and Blostein MD
- Subjects
- CSK Tyrosine-Protein Kinase, Cell Proliferation, Cell Survival, Human Umbilical Vein Endothelial Cells, Humans, Membrane Microdomains chemistry, Phosphorylation, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins c-akt metabolism, Receptor Protein-Tyrosine Kinases metabolism, Signal Transduction, Thrombosis metabolism, src-Family Kinases metabolism, Axl Receptor Tyrosine Kinase, Caveolin 1 metabolism, Endothelial Cells cytology, Intercellular Signaling Peptides and Proteins metabolism, Thromboplastin metabolism
- Abstract
Background: Gas6 has been shown to interact with Axl in endothelial cells and to induce several signaling pathways involved in cell survival and proliferation. However, the interaction of Gas6/Axl with lipid raft/caveolin-1 in endothelial cells and its role in thrombosis are unknown., Objectives: We tested whether Axl and/or caveolin-1 is involved in Gas6-induced Akt, ERK1/2, and c-Src activation leading to altered tissue factor expression in endothelial cells., Methods: Gas6-treated endothelial cells were transfected with small interfering RNA (siRNA) for Axl, caveolin-1, c-Src, and Akt or treated with pharmacological inhibitors of c-Src and ERK1/2. Sucrose gradient centrifugation and confocal microscopy were used to study lipid raft/caveolin-1-enriched fractions. Akt, ERK1/2, p38, and c-Src activation was analyzed by Western blot analysis. Tissue factor expression was assessed by real-time quantitative polymerase chain reaction and immunofluorescence., Results and Conclusion: Gas6 induced Axl and c-Src localization into lipid raft/caveolin-1-enriched fractions. Gas6 increased the phosphorylation of Akt, ERK1/2, and c-Src but not p38. Using siRNA, we demonstrated that Axl is required for Akt, ERK1/2, and c-Src activation after Gas6 stimulation. siRNA for caveolin-1 blocked Gas6-induced phosphorylation of Akt, ERK1/2, and c-Src. c-Src downregulation inhibited Gas6-induced Akt but not ERK1/2 phosphorylation. Finally, Gas6 increased tissue factor mRNA and protein expression in endothelial cells. Tissue factor expression was blocked by siRNA for Axl, caveolin-1, or Akt as well as c-Src inhibition. These data demonstrate that the signaling pathway Gas6/Axl/caveolin-1/c-Src/Akt is required for tissue factor expression in endothelial cells, providing mechanistic insight into how Gas6 exerts its prothrombotic role in the vasculature., (© 2013 International Society on Thrombosis and Haemostasis.)
- Published
- 2014
- Full Text
- View/download PDF
29. Amphiphilic peptide-loaded nanofibrous calcium phosphate microspheres promote hemostasis in vivo.
- Author
-
Wu J, Lemarié CA, Barralet J, and Blostein MD
- Subjects
- Adsorption, Animals, Factor X metabolism, Liver drug effects, Liver pathology, Male, Mice, Mice, Inbred C57BL, Tail, Calcium Phosphates chemistry, Hemostasis drug effects, Hemostatics pharmacology, Microspheres, Nanofibers chemistry, Peptides pharmacology, Surface-Active Agents pharmacology
- Abstract
Most fatalities from trauma occur due to severe blood loss. There is a need for improved hemostatic biomaterials that can address this problem. The aim of this study was to determine the in vivo efficacy of nanofibrous microspheres (NFM) loaded with hemostatic peptides, specifically ideal amphipathic peptides (IAP) that have been demonstrated to possess both procoagulant and antifibrinolyic activities. We demonstrate that IAP can be coupled to NFM (IAP-NFM) to form matrices that exhibit substantial hemostatic activity. IAP-NFM matrices were compared to a commercial zeolitic hemostatic biomaterial (QuikClot) and have superior efficacy in reducing bleeding in vivo. In both a murine tail transection and a murine hepatic injury model, bleeding times were significantly reduced (P<0.05) with the use of IAP-NFM as compared with equal masses of either QuikClot or NFM alone, or no treatment. Importantly, histological examination revealed no tissue injury when IAP-NFM or NFM were applied to hepatic lacerations. In contrast, QuikClot caused widespread hepatocyte degeneration and necrosis, with higher average injury zone thickness as determined by semiquantitative analysis. In summary, NFM was able to maintain the pro-coagulant properties of IAP in our preclinical model, caused no observable tissue damage at the site of application and had better performance than QuikClot controls., (Copyright © 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
30. Vascular Gas6 contributes to thrombogenesis and promotes tissue factor up-regulation after vessel injury in mice.
- Author
-
Robins RS, Lemarié CA, Laurance S, Aghourian MN, Wu J, and Blostein MD
- Subjects
- Animals, Blood Platelets metabolism, Blood Vessels pathology, Endothelial Cells metabolism, Gene Expression Regulation, Intercellular Signaling Peptides and Proteins metabolism, Male, Mice, Mice, Knockout, Thromboplastin metabolism, Thrombosis metabolism, Blood Vessels metabolism, Intercellular Signaling Peptides and Proteins genetics, Thromboplastin genetics, Thrombosis genetics
- Abstract
Gas6 (growth-arrest specific gene 6) plays a role in thrombus stabilization. Gas6 null (-/-) mice are protected from lethal venous and arterial thromboembolism through platelet signaling defects induced only by 5 μM ADP and 10 μM of the thromboxane analog, U46619. This subtle platelet defect, despite a dramatic clinical phenotype, raises the possibility that Gas6 from a source other than platelets contributes to thrombus formation. Thus, we hypothesize that Gas6 derived from the vascular wall plays a role in venous thrombus formation. Bone marrow transplantation and platelet depletion/reconstitution experiments generating mice with selective ablations of Gas6 from either the hematopoietic or nonhematopoietic compartments demonstrate an approximately equal contribution by Gas6 from both compartments to thrombus formation. Tissue factor expression was significantly reduced in the vascular wall of Gas6(-/-) mice compared with WT. In vitro, thrombin-induced tissue factor expression was reduced in Gas6(-/-) endothelial cells compared with wild-type endothelium. Taken together, these results demonstrate that vascular Gas6 contributes to thrombus formation in vivo and can be explained by the ability of Gas6 to promote tissue factor expression and activity. These findings support the notion that vascular wall-derived Gas6 may play a pathophysiologic role in venous thromboembolism.
- Published
- 2013
- Full Text
- View/download PDF
31. Growth arrest-specific gene 6 (gas6) and vascular hemostasis.
- Author
-
Laurance S, Lemarié CA, and Blostein MD
- Subjects
- Animals, Arteries metabolism, Atherosclerosis metabolism, Humans, Mice, Neoplasms metabolism, Thrombosis metabolism, Veins metabolism, Hemostasis physiology, Intercellular Signaling Peptides and Proteins metabolism
- Abstract
Gas6 (growth arrest-specific 6) belongs structurally to the family of plasma vitamin K-dependent proteins. Gas6 has a high structural homology with the natural anticoagulant protein S, sharing the same modular composition. Interestingly, despite the presence of a γ-carboxyglutamic acid domain in its structure, no role in the coagulation cascade has been identified for gas6. Gas6 has been shown to be involved in vascular homeostasis and more precisely is involved in proliferation, apoptosis, efferocytosis, leukocyte migration, and sequestration and platelet aggregation. It is also involved in the activation of different cell types, from platelets to endothelial and vascular smooth muscle cells. Thus, it has been shown to play a role in several pathophysiological processes such as atherosclerosis, cancer, and thrombosis. Interestingly, studies using gas6 null mice highlighted that gas6 may represent a novel potential target for anticoagulant therapy, because these animals are protected from lethal venous thromboembolism without excessive bleeding. However, the mechanism in thrombus occurrence remains to be further explored. In the present review, we will focus on the role of gas6 in innate immunity, atherosclerosis, thrombosis, and cancer-related events.
- Published
- 2012
- Full Text
- View/download PDF
32. In vivo monitoring of venous thrombosis in mice.
- Author
-
Aghourian MN, Lemarié CA, and Blostein MD
- Subjects
- Animals, Anticoagulants pharmacology, Chlorides, Dalteparin pharmacology, Disease Models, Animal, Ferric Compounds, Ligation, Male, Mice, Mice, Inbred C57BL, Time Factors, Vena Cava, Inferior surgery, Venous Thrombosis blood, Venous Thrombosis drug therapy, Venous Thrombosis etiology, Blood Coagulation drug effects, Monitoring, Physiologic methods, Ultrasonography, Doppler, Color, Ultrasonography, Doppler, Pulsed, Vena Cava, Inferior diagnostic imaging, Venous Thrombosis diagnostic imaging
- Abstract
Background: Venous thrombosis (VT) is an important cause of morbidity and mortality in clinical medicine. Animal models studying venous thrombosis are scarce and, in most cases, very crude and rely on sacrificing the animals to excise formed thrombi. Developing an in vivo murine model of venous thrombosis can be a powerful tool for studying venous thrombosis., Objectives: We sought to use a high-frequency ultrasound system (HFUS) to dynamically and non-invasively monitor thrombus formation in the inferior vena cava (IVC) of mice., Methods: We developed a murine model of venous thrombosis using, for detection, the Vevo 770(®), a micro-imaging HFUS. Two different thrombosis models were used to generate thrombi in the IVC of C57Bl/6NCr mice: (i) ligation and (ii) application of ferric chloride (FeCl(3)). We then assessed venous thrombosis by HFUS., Results: In both models, measurements of the clot pathologically correlated favorably with measurements acquired with HFUS. Thrombus develops less than an hour after ligation or FeCl(3) -induced injury of the IVC and the size of the clot increases over time for up to 24 h. Importantly, we demonstrate that HFUS can be used to monitor the effect of an anticoagulant such as dalteparin until complete resolution of the thrombus., Conclusions: These data show that HFUS assesses venous thrombosis in mice reliably and non-invasively. Developing a murine model of thrombosis using more accurate, and clinically more relevant, techniques such as ultrasonography, is a step towards a better understanding of the pathophysiology of venous thromboembolism., (© 2011 International Society on Thrombosis and Haemostasis.)
- Published
- 2012
- Full Text
- View/download PDF
33. Inactivation of endothelial proprotein convertase 5/6 decreases collagen deposition in the cardiovascular system: role of fibroblast autophagy.
- Author
-
Marchesi C, Essalmani R, Lemarié CA, Leibovitz E, Ebrahimian T, Paradis P, Seidah NG, Schiffrin EL, and Prat A
- Subjects
- Animals, Collagen genetics, Coronary Vessels pathology, Endothelial Cells pathology, Fibroblasts pathology, Humans, Insulin-Like Growth Factor I genetics, Insulin-Like Growth Factor I metabolism, Mice, Mice, Transgenic, Myocardium metabolism, Myocardium pathology, Organ Size genetics, Proprotein Convertase 5 genetics, Proteolysis, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction genetics, TOR Serine-Threonine Kinases genetics, TOR Serine-Threonine Kinases metabolism, Autophagy, Collagen biosynthesis, Coronary Vessels metabolism, Endothelial Cells enzymology, Fibroblasts enzymology, Proprotein Convertase 5 metabolism, Vascular Stiffness
- Abstract
Proprotein convertase (PC) 5/6 belongs to a family of secretory proteases involved in proprotein proteolysis. Several studies suggest a role for PC5/6 in cardiovascular disease. Because lethality at birth of mice lacking PC5/6 precluded elucidation of its function in the adult, we generated mice in which the gene of PC5/6 (pcsk5) is specifically inactivated in endothelial cells (ecKO), which are viable and do not exhibit overt abnormalities. In order to uncover the function of PC5/6 in the cardiovascular system, the effect of ecKO was studied in aging mice. In 16 to 18-month-old ecKO mice, the left ventricle (LV) mass, media cross-sectional area of aorta and coronary arteries, and media-to-lumen ratio of mesenteric arteries were decreased. The LV presented decreased diastolic function, and mesenteric arteries showed decreased stiffness. Collagen was decreased in the LV myocardial interstitium and perivascularly in coronary arteries and aorta. Cardiovascular hypotrophy likely develops with aging, since no significant changes were observed in 2-month-old ecKO mice. Fibroblasts, as a source of collagen in myocardium and vasculature, may play a role in the decrease in collagen deposition. Fibroblasts co-cultured with ecKO endothelial cells showed decreased collagen production, decreased insulin-like growth factor (IGF)-1/Akt/mTOR signaling, and enhanced autophagic activation. PC5/6 inactivation in endothelial cells results in cardiovascular hypotrophy associated with decreased collagen deposition, decreased LV diastolic function, and vascular stiffness, suggesting a trophic role of endothelial PC5/6 in the cardiovascular system, likely mediated by IGF-1/Akt/mTOR signaling and control of autophagy.
- Published
- 2011
- Full Text
- View/download PDF
34. Exposure to moderate arsenic concentrations increases atherosclerosis in ApoE-/- mouse model.
- Author
-
Lemaire M, Lemarié CA, Molina MF, Schiffrin EL, Lehoux S, and Mann KK
- Subjects
- Animals, Apolipoproteins E genetics, Cholesterol, HDL blood, Cytokines analysis, Cytokines drug effects, Disease Models, Animal, Dose-Response Relationship, Drug, Fluorescent Antibody Technique, Gene Expression, Gene Expression Regulation, Liver X Receptors, Male, Mice, Mice, Knockout, Orphan Nuclear Receptors genetics, Orphan Nuclear Receptors metabolism, Risk Factors, Arsenic toxicity, Atherosclerosis chemically induced, Atherosclerosis pathology
- Abstract
Arsenic is a widespread environmental contaminant to which millions of people are exposed worldwide. Exposure to arsenic is epidemiologically linked to increased cardiovascular disease, such as atherosclerosis. However, the effects of moderate concentrations of arsenic on atherosclerosis formation are unknown. Therefore, we utilized an in vivo ApoE(-/-) mouse model to assess the effects of chronic moderate exposure to arsenic on plaque formation and composition in order to facilitate mechanistic investigations. Mice exposed to 200 ppb arsenic developed atherosclerotic lesions, a lower exposure than previously reported. In addition, arsenic modified the plaque content, rendering them potentially less stable and consequently, potentially more dangerous. Moreover, we observed that the lower exposure concentration was more atherogenic than the higher concentration. Arsenic-enhanced lesions correlated with several proatherogenic molecular changes, including decreased liver X receptor (LXR) target gene expression and increased proinflammatory cytokines. Significantly, our observations suggest that chronic moderate arsenic exposure may be a greater cardiovascular health risk than previously anticipated.
- Published
- 2011
- Full Text
- View/download PDF
35. The gift of Gab1 (Grb-2-associated binder 1).
- Author
-
Lemarié CA and Lehoux S
- Subjects
- Adaptor Proteins, Signal Transducing, Angiogenic Proteins metabolism, Animals, Cell Movement, Cell Proliferation, Cell Survival, Disease Models, Animal, Endothelium, Vascular pathology, Endothelium, Vascular physiopathology, Hindlimb, Ischemia pathology, Ischemia physiopathology, Mice, Recovery of Function, Regional Blood Flow, Signal Transduction, Endothelium, Vascular metabolism, Ischemia metabolism, Muscle, Skeletal blood supply, Neovascularization, Physiologic, Phosphoproteins metabolism
- Published
- 2011
- Full Text
- View/download PDF
36. Mthfr deficiency induces endothelial progenitor cell senescence via uncoupling of eNOS and downregulation of SIRT1.
- Author
-
Lemarié CA, Shbat L, Marchesi C, Angulo OJ, Deschênes ME, Blostein MD, Paradis P, and Schiffrin EL
- Subjects
- Animals, Cell Differentiation genetics, Down-Regulation, Female, Homocystinuria genetics, Hyperhomocysteinemia drug therapy, Hyperhomocysteinemia enzymology, Hyperhomocysteinemia genetics, Methylenetetrahydrofolate Reductase (NADPH2) deficiency, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Mice, Muscle Spasticity genetics, Nitric Oxide metabolism, Oxidative Stress drug effects, Oxidative Stress genetics, Psychotic Disorders genetics, Pterins pharmacology, Reactive Oxygen Species, Telomere metabolism, Cellular Senescence genetics, Endothelial Cells enzymology, Nitric Oxide Synthase Type III metabolism, Sirtuin 1 metabolism, Stem Cells enzymology
- Abstract
Hyperhomocysteinemia (HHcy) has been shown to induce endothelial dysfunction in part as a result of enhanced oxidative stress. Function and survival of endothelial progenitor cells (EPCs, defined as sca1(+) c-kit(+) flk-1(+) bone marrow-derived cells), which significantly contribute to neovascularization and endothelial regeneration, depend on controlled production of reactive oxygen species (ROS). Mice heterozygous for the gene deletion of methylenetetrahydrofolate reductase (Mthfr(+/-)) have a 1.5- to 2-fold elevation in plasma homocysteine. This mild HHcy significantly reduced the number of circulating EPCs as well as their differentiation. Mthfr deficiency was also associated with increased ROS production and reduced nitric oxide (NO) generation in Mthfr(+/-) EPCs. Treatment of EPCs with sepiapterin, a precursor of tetrahydrobiopterin (BH(4)), a cofactor of endothelial nitric oxide synthase (eNOS), significantly reduced ROS and improved NO production. mRNA and protein expression of eNOS and the relative amount of eNOS dimer compared with monomer were decreased by Mthfr deficiency. Impaired differentiation of EPCs induced by Mthfr deficiency correlated with increased senescence, decreased telomere length, and reduced expression of SIRT1. Addition of sepiapterin maintained cell senescence and SIRT1 expression at levels comparable to the wild type. Taken together, these results demonstrate that Mthfr deficiency impairs EPC formation and increases EPC senescence by eNOS uncoupling and downregulation of SIRT1.
- Published
- 2011
- Full Text
- View/download PDF
37. Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress.
- Author
-
Ebrahimian T, Li MW, Lemarié CA, Simeone SM, Pagano PJ, Gaestel M, Paradis P, Wassmann S, and Schiffrin EL
- Subjects
- Angiotensin II, Animals, Aorta metabolism, Aorta physiopathology, Blood Pressure genetics, Blood Pressure physiology, Blotting, Western, Cell Proliferation, Cells, Cultured, Chemokine CCL2 genetics, Chemokine CCL2 metabolism, Hypertension chemically induced, Hypertension physiopathology, Inflammation chemically induced, Inflammation physiopathology, Intracellular Signaling Peptides and Proteins genetics, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Muscle, Smooth, Vascular cytology, Muscle, Smooth, Vascular metabolism, NADPH Oxidases metabolism, NF-kappa B metabolism, Protein Serine-Threonine Kinases genetics, RNA Interference, Reverse Transcriptase Polymerase Chain Reaction, Superoxides metabolism, Vascular Cell Adhesion Molecule-1 metabolism, Hypertension metabolism, Inflammation metabolism, Intracellular Signaling Peptides and Proteins metabolism, Oxidative Stress, Protein Serine-Threonine Kinases metabolism
- Abstract
Vascular oxidative stress and inflammation play an important role in angiotensin II-induced hypertension, and mitogen-activated protein kinases participate in these processes. We questioned whether mitogen-activated protein kinase-activated protein kinase 2 (MK2), a downstream target of p38 mitogen-activated protein kinase, is involved in angiotensin II-induced vascular responses. In vivo experiments were performed in wild-type and Mk2 knockout mice infused intravenously with angiotensin II. Angiotensin II induced a 30 mm Hg increase in mean blood pressure in wild-type that was delayed in Mk2 knockout mice. Angiotensin II increased superoxide production and vascular cell adhesion molecule-1 in blood vessels of wild-type but not in Mk2 knockout mice. Mk2 knockdown by small interfering RNA in mouse mesenteric vascular smooth muscle cells caused a 42% reduction in MK2 protein and blunted the angiotensin II-induced 40% increase of MK2 expression. Mk2 knockdown blunted angiotensin II-induced doubling of intracellular adhesion molecule-1 expression, 2.4-fold increase of nuclear p65, and 1.4-fold increase in Ets-1. Mk2 knockdown abrogated the angiotensin II-induced 4.7-fold and 1.3-fold increase of monocyte chemoattractant protein-1 mRNA and protein. Angiotensin II enhanced reactive oxygen species levels (by 29%) and nicotinamide adenine dinucleotide phosphate oxidase activity (by 48%), both abolished by Mk2 knockdown. Reduction of MK2 blocked angiotensin II-induced p47phox translocation to the membrane, associated with a 53% enhanced catalase expression. Angiotensin II-induced increase of MK2 was prevented by the nicotinamide adenine dinucleotide phosphate oxidase inhibitor Nox2ds-tat. Mk2 small interfering RNA prevented the angiotensin II-induced 30% increase of proliferation. In conclusion, MK2 plays a critical role in angiotensin II signaling, leading to hypertension, oxidative stress via activation of p47phox and inhibition of antioxidants, and vascular inflammation and proliferation.
- Published
- 2011
- Full Text
- View/download PDF
38. The angiotensin II type 2 receptor in cardiovascular disease.
- Author
-
Lemarié CA and Schiffrin EL
- Subjects
- Animals, Blood Pressure physiology, Cardiovascular Diseases pathology, Cardiovascular Diseases physiopathology, Cardiovascular Diseases therapy, Humans, Signal Transduction, Vasodilation physiology, Cardiovascular Diseases metabolism, Receptor, Angiotensin, Type 2 metabolism
- Abstract
Angiotensin II (Ang II) is considered the major final mediator of the renin-angiotensin system. The actions of Ang II have been implicated in many cardiovascular conditions, such as hypertension, atherosclerosis, coronary heart disease, restenosis, and heart failure. Ang II can act through two different receptors: Ang II type 1 (AT(1)) receptor and Ang II type 2 (AT(2)) receptor. The AT(1) receptor is ubiquitously expressed in the cardiovascular system and mediates most of the physiological and pathophysiological actions of Ang II. The AT(2) receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT(2) receptor can be modulated by pathological states associated with tissue remodelling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. The precise role of the AT(2) receptor remains under debate. However, it appears that the AT(2) receptor plays a vasodilatory role, and may be enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis. Signalling pathways induced by the stimulation of the AT(2) receptor are poorly understood, but three main mechanisms have been described: (a) activation of protein phosphatases causing protein dephosphorylation; (b) activation of bradykinin/nitric oxide/cyclic guanosine 3',5'-monophosphate pathway; and (c) stimulation of phospholipase A(2) and release of arachidonic acid. Vasodilatory effects of the AT(2) receptor, probably the only well-established role of the AT(2) receptor, have been attributed to the second of these mechanisms. The participation of the AT(2) receptor in cardiovascular remodelling and inflammation is more controversial. In vitro, AT(2) receptor stimulation clearly inhibits cardiac and vascular smooth muscle growth and proliferation, and stimulates apoptosis. In vivo, the situation is less clear, and depending on the studies, the AT(2) receptor appears to be required for cardiac hypertrophic growth or contrariwise, the AT(2) receptor has demonstrated no effects on cardiac hypertrophy. Similar controversial findings have been reported in atherosclerosis. Here we discuss the role of the AT(2) receptor on cardiovascular structure and disease, and the signalling pathways induced by its activation.
- Published
- 2010
- Full Text
- View/download PDF
39. Extracellular matrix alterations in hypertensive vascular remodeling.
- Author
-
Lemarié CA, Tharaux PL, and Lehoux S
- Subjects
- Animals, Extracellular Matrix enzymology, Humans, Hypertension genetics, NF-kappa B metabolism, Peptide Hydrolases genetics, Peptide Hydrolases metabolism, Signal Transduction genetics, Extracellular Matrix metabolism, Hypertension metabolism, Hypertension physiopathology, Signal Transduction physiology
- Abstract
Vascular cells are very sensitive to their hemodynamic environment. Any change in blood pressure or blood flow can be sensed by endothelial and vascular smooth muscle cells and ultimately results in structural modifications within the vascular wall that accommodate the new conditions. In the case of hypertension, the increase in arterial stretch stimulates vessel thickening to normalize the tensile forces. This process requires modification of the extracellular matrix and of cell-matrix interactions, which mainly involves extracellular proteases. In hypertension, chronic exposure of the arterial wall to stretch leads to vascular remodeling, arterial stiffness and calcification, which finally affect target organ function. This review surveys how mechanical stretch regulates extracellular proteases, considering the signaling pathways involved and the consequences on the cardiovascular system., (2009 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
40. Immune regulation and vascular inflammation in genetic hypertension.
- Author
-
Viel EC, Lemarié CA, Benkirane K, Paradis P, and Schiffrin EL
- Subjects
- Animals, Aorta metabolism, Aorta pathology, Aorta physiopathology, Cell Count, Disease Models, Animal, Forkhead Transcription Factors metabolism, Genetic Predisposition to Disease, Interleukin-10 metabolism, Male, Rats, Rats, Inbred BN, Rats, Inbred Dahl, Rats, Inbred Strains, T-Lymphocytes, Regulatory pathology, Transforming Growth Factor beta1 metabolism, Vasculitis metabolism, Vasculitis pathology, Adaptive Immunity physiology, Blood Pressure physiology, Hypertension genetics, Hypertension physiopathology, Vasculitis physiopathology
- Abstract
Immune cells have been implicated in the pathogenesis of hypertension. We hypothesized that under the influence of chromosome (chr)2, T lymphocytes contribute to vascular inflammation in genetic salt-sensitive hypertension. Normotensive (Brown Norway), hypertensive (Dahl salt-sensitive), and consomic rats (SSBN2; in which chr2 has been transferred from Brown Norway to Dahl rats) were studied. Systolic blood pressure, measured by tail cuff, and aortic preproendothelin mRNA, measured by quantitative RT-PCR, were elevated in Dahl rats compared with Brown Norway rats and were reduced in SSBN2 rats compared with Dahl rats (P < 0.01). Compared with Brown Norway rats, Dahl rats exhibited increased inflammatory markers and mediators such as nuclear translocation of the aortic p65 subunit of NF-kappaB as well as VCAM-1, ICAM-1, chemokine (C-C motif) receptor 5, and CD4 mRNA, all of which were reduced in SSBN2 rats. Aortic CD8 mRNA was equally increased in Dahl and SSBN2 rats relative to Brown Norway rats. CD4(+) T cell infiltration in the aorta of SSBN2 rats was reduced compared with Dahl rats, whereas the aortic protein expression of Foxp3b and immunosuppressors transforming growth factor (TGF)-beta(1) and IL-10, the three markers associated with the regulatory T cell lineage, were enhanced in SSBN2 rats. Activation in vitro of T cells demonstrated that CD4(+)CD25(+) and CD8(+)CD25(+) cells (Tregs) produce IL-10 in SSBN2 rats. Thus, increased vascular inflammatory responses and hypertension in a genetic salt-sensitive hypertensive rodent model are reduced by transfer of chr2 from a normotensive strain, and this is associated with enhanced levels of immunosuppressive mediators.
- Published
- 2010
- Full Text
- View/download PDF
41. Countervailing vascular effects of rosiglitazone in high cardiovascular risk mice: role of oxidative stress and PRMT-1.
- Author
-
Savoia C, Ebrahimian T, Lemarié CA, Paradis P, Iglarz M, Amiri F, Javeshgani D, and Schiffrin EL
- Subjects
- Animals, Carotid Artery, Internal physiopathology, Cholesterol blood, Cholesterol, Dietary administration & dosage, Disease Models, Animal, Drug Evaluation, Preclinical methods, Endothelium, Vascular physiopathology, Female, Hyperhomocysteinemia blood, Hyperhomocysteinemia physiopathology, Methylenetetrahydrofolate Reductase (NADPH2) deficiency, Methylenetetrahydrofolate Reductase (NADPH2) genetics, Mice, Mice, Knockout, Nitrites blood, Oxidative Stress drug effects, Protein-Arginine N-Methyltransferases genetics, Rosiglitazone, Superoxides metabolism, Thiazolidinediones adverse effects, Hyperhomocysteinemia drug therapy, Oxidative Stress physiology, Protein-Arginine N-Methyltransferases physiology, Thiazolidinediones therapeutic use
- Abstract
In the present study, we tested the hypothesis that the PPARgamma (peroxisome-proliferator-activated receptor gamma) activator rosiglitazone improves vascular structure and function in aged hyperhomocysteinaemic MTHFR (methylene tetrahydrofolate reductase) gene heterozygous knockout (mthfr+/-) mice fed a HCD (high-cholesterol diet), a model of high cardiovascular risk. One-year-old mthfr+/- mice were fed or not HCD (6 mg x kg-1 of body weight x day-1) and treated or not with rosiglitazone (20 mg x kg-1 of body weight x day-1) for 90 days and compared with wild-type mice. Endothelium-dependent relaxation of carotid arteries was significantly impaired (-40%) only in rosiglitazone-treated HCD-fed mthfr+/- mice. Carotid M/L (media-to-lumen ratio) and CSA (cross-sectional area) were increased (2-fold) in mthfr+/- mice fed or not HCD compared with wild-type mice (P<0.05). Rosiglitazone reduced M/L and CSA only in mthfr+/- mice fed a normal diet. Superoxide production was increased in mthfr+/- mice fed HCD treated or not with rosiglitazone, whereas plasma nitrite was decreased by rosiglitazone in mice fed or not HCD. PRMT-1 (protein arginine methyltransferase-1), involved in synthesis of the NO (nitric oxide) synthase inhibitor ADMA (asymmetric omega-NG,NG-dimethylarginine), and ADMA were increased only in rosiglitazone-treated HCD-fed mthfr+/- mice. Rosiglitazone had both beneficial and deleterious vascular effects in this animal model of high cardiovascular risk: it prevented carotid remodelling, but impaired endothelial function in part through enhanced oxidative stress and increased ADMA production in mice at high cardiovascular risk.
- Published
- 2010
- Full Text
- View/download PDF
42. Aldosterone-induced activation of signaling pathways requires activity of angiotensin type 1a receptors.
- Author
-
Lemarié CA, Simeone SM, Nikonova A, Ebrahimian T, Deschênes ME, Coffman TM, Paradis P, and Schiffrin EL
- Subjects
- Angiotensin II metabolism, Animals, Cells, Cultured, JNK Mitogen-Activated Protein Kinases metabolism, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Mitogen-Activated Protein Kinase 1 metabolism, Mitogen-Activated Protein Kinase 3 metabolism, NF-kappa B metabolism, Phosphorylation, Proto-Oncogene Proteins c-fos genetics, Proto-Oncogene Proteins c-fos metabolism, RNA Interference, Receptor Cross-Talk, Receptor, Angiotensin, Type 1 deficiency, Receptor, Angiotensin, Type 1 genetics, Receptors, Mineralocorticoid genetics, Receptors, Mineralocorticoid metabolism, Time Factors, Transfection, Aldosterone metabolism, Muscle, Smooth, Vascular metabolism, Myocytes, Smooth Muscle metabolism, Receptor, Angiotensin, Type 1 metabolism, Signal Transduction
- Abstract
Rationale: Aldosterone has been shown to induce vascular damage, endothelial dysfunction, and myocardial fibrosis, which depend in part on activation of angiotensin II (Ang II)-mediated pathways. However, mechanisms underlying crosstalk between Ang II type 1 receptor (AT(1)R) and mineralocorticoid receptor (MR) are mostly unknown., Objectives: We tested whether the lack of Ang II type 1a receptor (AT(1a)R) or Ang II type 1b receptor (AT(1b)R) would decrease cellular effects induced by aldosterone., Methods and Results: We examined the effect of Ang II or aldosterone after transfection of mesenteric vascular smooth muscle cells (VSMCs) from C57Bl/6 mice with small interference RNA for AT(1a)R, AT(1b)R, or MR for 48 hours. Ang II and aldosterone separately induced ERK1/2, c-Jun NH2-terminal protein kinase (JNK), and nuclear factor (NF)-kappaB phosphorylation after a 20-minute stimulation. Small interference RNA for AT(1a)R downregulated phosphorylation of ERK1/2, JNK, and NF-kappaB after aldosterone stimulation compared to controls. Downregulation of AT(1b)R or MR only abolished the activation of NF-kappaB. In VSMCs from C57Bl/6 mice, aldosterone and Ang II induced the activation of the c-fos promoter from 30 minutes to 1 hour. This effect was blocked when using VSMCs from AT(1a)R knockout mice., Conclusion: We show for the first time that nongenomic and genomic effects of aldosterone are differentially dependent on activity of both AT(1a)R and AT(1b)R. Our data suggest that aldosterone augments AT(1)R-dependent activation of ERK1/2, JNK, and NF-kappaB in VSMCs. We provide mechanistic understanding and experimental in vitro support for the benefit of combination therapy with dual blockade of AT(1)R and MR to treat hypertension and progression of heart failure as reported in clinical studies and animal models.
- Published
- 2009
- Full Text
- View/download PDF
43. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone.
- Author
-
Lemarié CA, Paradis P, and Schiffrin EL
- Subjects
- Animals, Clinical Trials as Topic, Humans, Aldosterone metabolism, Angiotensin II metabolism, Signal Transduction
- Abstract
Angiotensin II (Ang II) is considered the main final mediator of the renin-angiotensin-aldosterone system (RAAS). The actions of Ang II have been implicated in many cardiovascular conditions, such as hypertension, atherosclerosis, coronary heart disease, restenosis after injury, and heart failure. The Ang II type 1 receptor (AT(1)R), a G-protein-coupled receptor, mediates most of the physiological and pathophysiological actions of Ang II. This receptor is predominantly expressed in cardiovascular cells, such as vascular smooth muscle cells where it activates various signaling cascades leading to vascular remodeling and inflammation. Besides Ang II, aldosterone has emerged as an important component and mediator of the effects of the RAAS. Aldosterone-induced genomic effects mediated through binding to the mineralocorticoid receptor (MR), a member of the steroid hormone receptor superfamily, which functions as a ligand-dependent transcription factor, are characterized by a delay of minutes to hours corresponding to a long series of subcellular events that include gene activation and protein synthesis. Besides its well-known genomic actions, there is evidence of aldosterone-mediated rapid effects which lead to the activation of ion channels and other signaling pathways. Some of the effects of aldosterone occur through similar pathways as Ang II-induced signaling events. Indeed, recent studies suggest complex interactions between Ang II and aldosterone: it has become evident that aldosterone may influence the signaling or trafficking of the AT(1)R. Thus, growing evidence demonstrates the existence of cross-talk between Ang II and aldosterone which could potentially modulate Ang II signal transduction. These interactions between Ang II and aldosterone activate specific signaling pathways, sometimes in ways distinct from those that they induce on their own, one which may lead to pathogenic effects on target organs. Here we focus on recent findings and concepts that suggest the existence of novel signaling mechanisms whereby the cross-talk between Ang II and aldosterone plays a role in cardiovascular disease. We also discuss the importance of investigating Ang II/aldosterone cross-talk as a mean of developing new therapeutic strategies to combat cardiovascular disease.
- Published
- 2008
- Full Text
- View/download PDF
44. Transforming growth factor-alpha mediates nuclear factor kappaB activation in strained arteries.
- Author
-
Lemarié CA, Tharaux PL, Esposito B, Tedgui A, and Lehoux S
- Subjects
- Animals, Carotid Arteries, Cells, Cultured, ErbB Receptors genetics, ErbB Receptors physiology, Mice, Mice, Mutant Strains, Organ Culture Techniques, Reactive Oxygen Species metabolism, Signal Transduction physiology, Stress, Mechanical, Endothelium, Vascular physiology, NF-kappa B metabolism, Transforming Growth Factor alpha physiology
- Abstract
Mechanical factors regulate both blood vessel growth and the development and progression of vascular disease. Acting on apoptotic and inflammatory signaling, the transcription factor nuclear factor kappaB (NF-kappaB) is a likely mediator of these processes. Nevertheless, pressure-dependent NF-kappaB activation pathways remain mostly unknown. Here we report that high intraluminal pressure induces reactive oxygen species (ROS) in arteries and that inhibition of NADPH oxidase prevents both the generation of ROS and the activation of NF-kappaB associated with high pressure. We also identify the epidermal growth factor receptor (EGFR) as a ROS-dependent signaling intermediate. In arteries from EGFR mutant mice (waved-2), pressure fails to activate NF-kappaB. Moreover, using vessels from EGFR ligand-deficient mice, we show that transforming growth factor (TGF)-alpha, but neither heparin-binding EGF-like growth factor nor epiregulin, transduces NF-kappaB activation by high pressure. Preventing the release of the active form of TGF-alpha also abolishes NF-kappaB induction by strain. The role of TGF-alpha signaling in vascular remodeling is substantiated in vivo; angiotensin II-induced activation of NF-kappaB and associated cell proliferation and wall thickening are much reduced in TGF-alpha-mutant mice compared with wild-type, despite equivalent hypertension in both groups. Conversely, apoptotic cells are detected only in vessels from hypertensive TGF-alpha-mutant mice, outlining the role of NF-kappaB in cell survival. Finally, the NF-kappaB activation pathway contrasts with that of extracellular signal-regulated kinase 1/2, which is activated by stretch through the EGFR but does not implicate TGF-alpha. Hence, our data identify TGF-alpha as a potential specific target to modulate mechanosensitive NF-kappaB activation and associated vascular remodeling.
- Published
- 2006
- Full Text
- View/download PDF
45. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling.
- Author
-
Lehoux S, Lemarié CA, Esposito B, Lijnen HR, and Tedgui A
- Subjects
- Animals, Carotid Arteries, Endothelial Cells enzymology, Endothelium, Vascular enzymology, Enzyme Induction, Hypertension pathology, Male, Matrix Metalloproteinase 2 biosynthesis, Matrix Metalloproteinase 2 genetics, Matrix Metalloproteinase 2 physiology, Matrix Metalloproteinase 9 biosynthesis, Matrix Metalloproteinase 9 genetics, Mice, Mice, Inbred C57BL, Muscle Cells enzymology, Muscle, Smooth, Vascular enzymology, Organ Culture Techniques, Stress, Mechanical, Hypertension enzymology, Matrix Metalloproteinase 9 physiology, Pressure
- Abstract
Background: High blood pressure causes a change in vascular wall structure involving altered extracellular matrix composition, but how this process occurs is not fully understood., Methods and Results: Using mouse carotid arteries maintained in organ culture for 3 days, we detected increased gelatin zymographic activity of matrix metalloproteinase (MMP)-2 (168+/-13%, P<0.05) in vessels kept at low intraluminal pressure (10 mm Hg) compared with vessels at 80 mm Hg (100%), whereas in vessels maintained at high pressure (150 mm Hg), both MMP-2 and MMP-9 activity was induced (182+/-32%, P<0.05, and 194+/-21%, P<0.01, respectively). MMPs were detected in endothelial and smooth muscle cells by immunohistochemistry and in situ gelatin zymography. In vessels at 150 mm Hg, MMP activation was associated with a shift in the pressure-diameter curve toward greater distensibility (P<0.01) compared with vessels at 80 mm Hg. However, distensibility was not altered in vessels at 10 mm Hg, in which only activated MMP-2 was detected. The role of MMPs in high pressure-induced vessel distensibility was confirmed by use of the MMP inhibitor FN-439, which prevented the shift in the pressure-diameter relationship. Furthermore, in carotid arteries from MMP-9-deficient mice, the pressure-dependent increase in MMP-2 and in situ gelatinolytic activity were maintained, but the upward shift in the pressure-diameter curve was abolished., Conclusions: MMP-9 seems to play a key role in the early stages of hypertensive vascular remodeling.
- Published
- 2004
- Full Text
- View/download PDF
46. Pressure-induced vascular activation of nuclear factor-kappaB: role in cell survival.
- Author
-
Lemarié CA, Esposito B, Tedgui A, and Lehoux S
- Subjects
- Animals, Carotid Arteries metabolism, Cell Survival physiology, DNA metabolism, Electrophoretic Mobility Shift Assay, I-kappa B Proteins metabolism, Immunohistochemistry, In Vitro Techniques, Kinetics, Male, Mice, Mice, Inbred C57BL, NF-KappaB Inhibitor alpha, Phosphorylation, Pressure, Stress, Mechanical, Blood Pressure physiology, Carotid Arteries physiology, Mechanotransduction, Cellular physiology, NF-kappa B metabolism
- Abstract
The effects of mechanical factors on nuclear factor (NF)-kappaB activation and its potential functional roles have been very little explored in the intact vessel. Thus, we chose to study the regulation of NF-kappaB by intraluminal pressure using an organ culture model of mouse carotid arteries maintained at 80 or 150 mm Hg during 24 hours. Gel shift analysis revealed an increase in the DNA-binding capacity of NF-kappaB in vessels at high pressure compared with vessels at normal pressure (304+/-49%; P<0.001). This coincided with reduced levels of the endogenous NF-kappaB inhibitor IkappaBalpha in arteries at 150 mm Hg (52+/-7%; P<0.001), as detected by Western blot. To study the functional role of the pressure-induced activation of NF-kappaB, we evaluated the rate of apoptosis (TUNEL method) in carotid arteries cultured with or without an inhibitor peptide blocking nuclear translocation of NF-kappaB. No apoptosis was detected in control arteries either at 80 or 150 mm Hg. However, in the presence of the NF-kappaB inhibitor peptide, we observed apoptosis in vessels at 80 mm Hg (5+/-1%; P<0.001 versus untreated controls), which was markedly increased in vessels at 150 mm Hg (14+/-2%; P<0.001). These results were corroborated by immunohistochemical analysis showing positive staining for cleaved caspase 3 in vessels at 80 mm Hg treated with the NF-kappaB inhibitor peptide, which was additionally enhanced in treated vessels at 150 mm Hg. Our findings demonstrate that high intraluminal pressure activates NF-kappaB in arteries. Moreover, the activation of NF-kappaB seems to play a key role in preventing apoptosis in vascular cells, especially when vessels are exposed to high intraluminal pressure.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.